<!DOCTYPE html>
<html lang="fr">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pipeline Bioinformatique</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@300;400;500;600;700&family=Playfair+Display:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="icon" href="data:image/svg+xml,<svg xmlns=%22http://www.w3.org/2000/svg%22 viewBox=%220 0 100 100%22><text y=%22.9em%22 font-size=%2290%22>üß¨</text></svg>">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/lightbox2/2.11.3/css/lightbox.min.css" rel="stylesheet" />
    <style>
        :root {
            --primary: #2a226b;
            --secondary: #ff0072;
            --accent: #00b4d8;
            --light-bg: #f8f9fa;
            --dark-bg: #1a1a2e;
            --text-light: #212529;
            --text-dark: #f0f0f0;
            --gray: #6c757d;
            --border-light: #dee2e6;
            --border-dark: #495057;
            --bg-image: url('A.JPG');
            --shadow-light: rgba(0, 0, 0, 0.1);
            --shadow-dark: rgba(0, 0, 0, 0.3);
        }

        .dark-mode {
            --primary: #8a83d6;
            --secondary: #ff4d9e;
            --accent: #00d4ff;
            --light-bg: #232333;
            --dark-bg: #f8f9fa;
            --text-light: #f0f0f0;
            --text-dark: #212529;
            --gray: #adb5bd;
            --border-light: #495057;
            --border-dark: #dee2e6;
            --shadow-light: rgba(255, 255, 255, 0.1);
            --shadow-dark: rgba(0, 0, 0, 0.1);
        }

        * { margin: 0; padding: 0; box-sizing: border-box; }
        html { scroll-behavior: smooth; font-size: 16px; }

        body {
            font-family: 'Montserrat', sans-serif;
            background-color: var(--light-bg);
            color: var(--text-light);
            line-height: 1.7;
            position: relative;
            transition: background-color 0.4s, color 0.4s;
        }

        body::before {
            content: ""; position: fixed; top: 0; left: 0; width: 100%; height: 100%;
            background-image: var(--bg-image); background-size: cover;
            background-position: center; background-attachment: fixed;
            opacity: 0.08; z-index: -1;
            transition: opacity 0.4s;
        }
        .dark-mode body::before {
            opacity: 0.05;
        }

        /* ANIMATIONS - Login & Logout Screens --- */
        .login-overlay {
            position: fixed; top: 0; left: 0; width: 100%; height: 100%;
            background: linear-gradient(135deg, var(--primary) 0%, #5e5499 100%);
            display: flex; justify-content: center; align-items: center;
            z-index: 1000; transition: opacity 0.5s ease, visibility 0.5s ease;
        }
        .login-overlay.hidden { opacity: 0; visibility: hidden; }
        .login-overlay::before {
            content: ""; position: absolute; top: 0; left: 0; width: 100%; height: 100%;
            background-image: url('https://images.unsplash.com/photo-1523050854058-8df90110c9f1?ixlib=rb-4.0.3&ixid=MnwxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8&auto=format&fit=crop&w=1470&q=80');
            background-size: cover; background-position: center; opacity: 0.1; z-index: -1;
            animation: bg-zoom 25s infinite alternate ease-in-out;
        }
        @keyframes bg-zoom {
            from { transform: scale(1); }
            to { transform: scale(1.1); }
        }
        .login-container {
            background: rgba(255, 255, 255, 0.92);
            padding: 2.5rem; border-radius: 15px; box-shadow: 0 15px 35px var(--shadow-dark);
            width: 100%; max-width: 400px; text-align: center;
            transform: translateY(-20px); opacity: 0; 
            animation: form-pop-in 0.8s 0.3s cubic-bezier(0.175, 0.885, 0.32, 1.275) forwards;
        }
        @keyframes form-pop-in {
            from { transform: translateY(-20px) scale(0.9); opacity: 0; }
            to { transform: translateY(0) scale(1); opacity: 1; }
        }
        .login-container.hidden-form { transform: translateY(20px) scale(0.95); opacity: 0; transition: all 0.4s ease-out; }
        .login-container h2 { color: var(--primary); margin-bottom: 1.5rem; font-family: 'Playfair Display', serif; font-weight: 600; font-size: 1.8rem; }
        .input-group { margin-bottom: 1.25rem; position: relative; }
        .input-group input {
            width: 100%; padding: 12px 15px; border: 2px solid var(--border-light);
            border-radius: 8px; font-size: 0.95rem; transition: all 0.3s ease;
            background-color: #fff; color: #333;
        }
        .input-group input:focus { border-color: var(--accent); outline: none; box-shadow: 0 0 0 3px rgba(0, 180, 216, 0.2); }
        
        .logout-message-overlay {
            position: fixed;
            top: 0; left: 0; width: 100%; height: 100%;
            background-color: var(--primary);
            color: white;
            display: none;
            justify-content: center;
            align-items: center;
            z-index: 999;
            opacity: 0;
            transition: opacity 0.7s ease-in-out;
        }
        .logout-message-overlay h2 {
            font-size: 2.5rem;
            font-family: 'Playfair Display', serif;
            text-align: center;
            padding: 1rem;
            transform: translateY(20px);
            opacity: 0;
        }
        .logout-message-overlay.show-message h2 {
            animation: fadeInZoom 1.2s cubic-bezier(0.25, 0.46, 0.45, 0.94) forwards;
        }
        @keyframes fadeInZoom {
            from { opacity: 0; transform: scale(0.8) translateY(20px); }
            to { opacity: 1; transform: scale(1) translateY(0); }
        }

        /* ANIMATIONS - Buttons & General --- */
        .btn {
            display: inline-block; padding: 12px 24px; background-color: var(--primary);
            color: white; border: none; border-radius: 8px; font-size: 1rem; font-weight: 500;
            cursor: pointer; transition: all 0.3s ease; text-transform: uppercase; letter-spacing: 0.5px;
            box-shadow: 0 2px 8px color-mix(in srgb, var(--primary) 30%, transparent);
        }
        .btn:hover { 
            background-color: color-mix(in srgb, var(--primary) 85%, black); 
            transform: translateY(-3px); 
            box-shadow: 0 6px 15px color-mix(in srgb, var(--primary) 50%, transparent); 
        }

        /* --- Main Content --- */
        .main-content { 
            display: none; 
            opacity: 0; 
            transition: opacity 0.8s ease-in-out;
        }
        .main-content.show { display: block; opacity: 1; }

        /* ANIMATIONS - Navbar --- */
        .navbar {
            position: fixed; top: 0; left: 0; width: 100%;
            background: var(--light-bg); color: var(--text-light);
            box-shadow: 0 2px 15px var(--shadow-light);
            z-index: 900; display: flex; flex-direction: column; padding: 0.8rem 2rem;
            transition: background-color 0.4s, color 0.4s, box-shadow 0.4s, transform 0.5s ease-out;
            transform: translateY(-100%);
        }
        .main-content.show .navbar {
            transform: translateY(0);
        }
        .navbar-top { display: flex; justify-content: space-between; align-items: center; width: 100%; }
        .logo img { height: 100px; margin-right: 15px; transition: transform 0.3s ease; }
        .logo img:hover { transform: scale(1.05); }
        .logo-text { font-family: 'Playfair Display', serif; font-weight: 700; color: var(--primary); font-size: 1.5rem; }
        .navbar-controls { display: flex; align-items: center; }

        .nav-tabs { display: flex; list-style: none; margin-top: 0.5rem; flex-wrap: nowrap; overflow-x: auto; padding-bottom: 5px;}
        .nav-tabs li { margin: 0.5rem 0.5rem; position: relative; flex-shrink: 0; }
        .nav-tabs a {
            text-decoration: none; color: var(--gray); font-weight: 500;
            font-size: 0.90rem;
            transition: all 0.3s ease; display: flex; align-items: center; padding: 0.3rem 0.5rem;
            border-radius: 5px; white-space: nowrap;
        }
        .nav-tabs a i { margin-right: 6px; font-size: 0.85rem; }
        .nav-tabs a:hover, .nav-tabs a.active { color: var(--primary); background-color: rgba(0,0,0,0.05);}
        .dark-mode .nav-tabs a:hover, .dark-mode .nav-tabs a.active {background-color: rgba(255,255,255,0.1);}

        .nav-tabs a::after {
            content: ''; position: absolute; bottom: -5px; left: 50%;
            width: 0; height: 3px; background-color: var(--accent); border-radius: 3px;
            transform: translateX(-50%);
            transition: width 0.4s cubic-bezier(0.25, 0.46, 0.45, 0.94);
        }
        .nav-tabs a.active::after {
            width: 60%;
        }

        /* Navbar Dropdown */
        .nav-item.dropdown { position: relative; }
        .dropdown-menu {
            display: none;
            position: absolute; top: 100%; left: 0;
            background-color: var(--light-bg);
            box-shadow: 0 8px 16px var(--shadow-light);
            border-radius: 0 0 8px 8px;
            z-index: 1000; min-width: 240px;
            padding: 0.5rem 0;
            border: 1px solid var(--border-light);
            transform: translateY(10px);
            opacity: 0;
            visibility: hidden;
            transition: transform 0.3s ease, opacity 0.3s ease, visibility 0.3s;
        }
        .dropdown-menu.show-dropdown {
            display: block;
            transform: translateY(0);
            opacity: 1;
            visibility: visible;
        }
        .dropdown-item {
            display: block; padding: 0.6rem 1.2rem;
            text-decoration: none; color: var(--text-light);
            font-size: 0.88rem;
            transition: background-color 0.2s, color 0.2s, padding-left 0.3s ease;
        }
        .dropdown-item:hover { background-color: var(--accent); color: white !important; padding-left: 1.5rem; }
        .dark-mode .dropdown-item:hover { color: var(--text-dark) !important; }

        .navbar-bottom { display: flex; width: 100%; margin-top: 0.5rem; align-items: center; }
        .search-container { position: relative; margin-right: 1rem; }
        .search-input {
            padding: 8px 15px 8px 35px; border: 1px solid var(--border-light);
            border-radius: 20px; width: 220px; transition: all 0.3s;
            background-color: white; color: #333;
        }
        .dark-mode .search-input { background-color: var(--gray); color: var(--text-dark); border-color: var(--border-dark);}
        .search-input:focus { outline: none; border-color: var(--accent); width: 250px; }
        .search-icon { position: absolute; left: 12px; top: 50%; transform: translateY(-50%); color: var(--gray); }

        /* Language Switcher Styles */
        .language-selector, .dark-mode-toggle, .logout-btn { margin-left: 1rem; }
        .language-selector { position: relative; }
        .language-btn, .dark-mode-toggle, .logout-btn {
            background: none; border: none; color: var(--gray); font-size: 1.1rem; cursor: pointer; transition: all 0.3s ease;
        }
        .language-btn { display: flex; align-items: center; }
        .language-flag { width: 20px; height: 15px; margin-right: 5px; border-radius: 2px; }
        .language-text-short { font-size: 0.85rem; font-weight: 500; margin-left: 5px; margin-right: 3px; color: var(--gray); }
        .dark-mode .language-text-short { color: var(--gray); }
        .language-dropdown {
            display: none;
            position: absolute;
            bottom: 100%; top: auto; right: 0;
            margin-bottom: 8px;
            background: var(--light-bg);
            border-radius: 8px 8px 0 0;
            box-shadow: 0 -8px 16px var(--shadow-light);
            padding: 0.5rem 0;
            z-index: 1000;
            min-width: 170px;
            transform: translateY(10px); opacity: 0; visibility: hidden;
            transition: transform 0.3s ease, opacity 0.3s ease, visibility 0.3s;
        }
        .language-dropdown.show-lang-dropdown {
            display: block;
            transform: translateY(0); opacity: 1; visibility: visible;
        }
        .language-option { padding: 0.5rem 1rem; display: flex; align-items: center; cursor: pointer; transition: all 0.2s; color: var(--text-light); }
        .language-option:hover { background-color: var(--accent); color: white; }
        .dark-mode-toggle:hover { color: var(--primary); transform: rotate(30deg) scale(1.1); }
        .logout-btn:hover { color: var(--secondary); transform: scale(1.1); }
        
        /* --- NOUVELLES ANIMATIONS - Content Sections --- */
        .content-container { 
            margin-top: 150px; padding: 2rem 1rem; 
            opacity: 0;
            transform: translateY(20px);
            transition: opacity 0.6s ease-out 0.3s, transform 0.6s ease-out 0.3s;
        }
        .main-content.show .content-container {
            opacity: 1;
            transform: translateY(0);
        }

        .tab-content { 
            display: none; 
            animation: fadeIn 0.7s ease-in-out;
        }
        @keyframes fadeIn {
            from { opacity: 0; } to { opacity: 1; }
        }
        .tab-content.active { display: block; }
        
        /* ---  Animation on Scroll  --- */
        .institution-header, .title-page, .content-section, .figure, .data-table-container, .pipeline-step, .contact-card, .work-plan {
            opacity: 0;
            transform: translateY(40px);
            transition: opacity 0.8s ease-out, transform 0.8s ease-out;
        }
        .is-visible {
             opacity: 1 !important; 
             transform: translateY(0) !important;
        }

        .institution-header {
            display: flex;
            align-items: center;
            justify-content: space-between;
            text-align: center;
            margin-bottom: 2rem;
            padding: 1.5rem 2rem;
            background: var(--light-bg);
            border-radius: 12px;
            box-shadow: 0 5px 20px var(--shadow-light);
            position: relative;
        }
        .institution-text-content { flex-grow: 1; text-align: center; padding: 0 1rem; }
        .institution-side-logo { height: 100px; width: auto; flex-shrink: 0; }
        .institution-top-line { display: none; }
        .institution-line { font-weight: 500; color: var(--gray); margin-bottom: 0.5rem; font-size: 1rem; }

        .title-page {
            text-align: center; padding: 2.5rem 1rem;
            background: linear-gradient(135deg, color-mix(in srgb, var(--primary) 5%, white) 0%, color-mix(in srgb, var(--accent) 10%, white) 100%);
            border-radius: 12px; margin-bottom: 2rem;
        }
        .dark-mode .title-page { background: linear-gradient(135deg, color-mix(in srgb, var(--primary) 15%, #121212) 0%, color-mix(in srgb, var(--accent) 20%, #121212) 100%); }
        .title-page h2 { font-family: 'Playfair Display', serif; font-size: 1.8rem; color: var(--primary); margin-bottom: 1.5rem; font-weight: 600; }
        .authors strong { display: block; color: var(--text-light);  margin-top: 0.3rem; }

        .promo { font-weight: 600; color: var(--primary); margin-bottom: 1.5rem; font-size: 1.05rem; }

        .content-section {
            background: var(--light-bg); padding: 2rem; border-radius: 12px;
            box-shadow: 0 5px 20px var(--shadow-light); margin-bottom: 2rem;
        }
        .content-section h3, .content-section h4 {
            font-family: 'Playfair Display', serif; color: var(--primary);
            margin-bottom: 1.2rem; font-weight: 600; position: relative; padding-bottom: 0.4rem;
        }
        .content-section h3 { font-size: 1.5rem; }
        .content-section h4 { font-size: 1.3rem; color: color-mix(in srgb, var(--primary) 85%, black); margin-top:1.5rem;}
        .content-section h3::after {
            content: ''; position: absolute; bottom: 0; left: 0; width: 50px; height: 3px;
            background-color: var(--accent); border-radius: 3px;
        }
        .content-section p { margin-bottom: 1rem; font-size: 1rem; }

        /* Tables */
        .data-table-container { margin: 1.5rem 0; }
        .data-table {
            width: 100%; border-collapse: collapse; 
            box-shadow: 0 0 15px var(--shadow-light); border-radius: 8px; overflow: hidden;
        }
        .data-table th { background-color: var(--primary); color: white; font-weight: 500; padding: 12px 15px; text-align: left; }
        .data-table td { padding: 12px 15px; border-bottom: 1px solid var(--border-light); transition: background-color 0.3s; }
        .data-table tr:last-child td { border-bottom: none; }
        .data-table tr:nth-child(even) { background-color: color-mix(in srgb, var(--light-bg) 95%, #ccc) ; }
        .dark-mode .data-table tr:nth-child(even) { background-color: color-mix(in srgb, var(--light-bg) 90%, #fff) ; }
        .data-table tr:hover td { background-color: color-mix(in srgb, var(--accent) 15%, white); }
        .dark-mode .data-table tr:hover td { background-color: color-mix(in srgb, var(--accent) 25%, black); }
        .table-responsive { overflow-x: auto; }


        /* Images & Figures */
        .figure { margin: 1.5rem 0; text-align: center; }
        .figure img, .pipeline-step img {
            max-width: 100%; height: auto; border-radius: 8px;
            box-shadow: 0 8px 25px var(--shadow-light);
            transition: transform 0.4s ease, box-shadow 0.4s ease;
            display: block; margin-left: auto; margin-right: auto; cursor: pointer;
        }
        .figure img:hover, .pipeline-step img:hover { transform: scale(1.03); box-shadow: 0 12px 30px var(--shadow-dark); }
        .figure-caption { margin-top: 0.6rem; font-style: italic; color: var(--gray); font-size: 0.85rem; }

        .horizontal-layout { display: flex; flex-direction: row; align-items: flex-start; gap: 20px; flex-wrap: wrap; }
        .text-content { flex: 1 1 60%; min-width: 300px; }
        .figure.inline-figure { flex: 1 1 35%; min-width: 250px; margin: 0; }

        .image-gallery { display: flex; flex-direction: row; gap: 15px; padding: 15px 0; overflow-x: auto; scroll-snap-type: x mandatory; }
        .image-gallery a { scroll-snap-align: center; flex-shrink: 0; }
        .image-gallery img { height: 250px; width: auto; border-radius: 20px; object-fit: cover; }

        /* NOUVELLES ANIMATIONS - Lists */
        .styled-list { list-style-type: none; margin: 1.2rem 0; padding-left: 0; }
        .styled-list li { margin-bottom: 0.8rem; padding-left: 1.8rem; position: relative; }
        .styled-list li::before {
            content: '‚Ä¢'; color: var(--accent); font-size: 1.5rem;
            position: absolute; left: 0; top: -2px;
            transition: transform 0.3s cubic-bezier(0.175, 0.885, 0.32, 1.275);
        }
        .styled-list li:hover::before {
            transform: scale(1.3) rotate(180deg);
        }

        .highlight, .gene-info-trigger {
            background-color: color-mix(in srgb, var(--accent) 15%, transparent);
            padding: 0.2rem 0.4rem; border-radius: 4px; font-weight: 600; color: var(--primary);
            cursor: pointer; border-bottom: 1px dashed var(--primary);
            transition: background-color 0.3s, color 0.3s;
        }
        .highlight:hover, .gene-info-trigger:hover {
            background-color: color-mix(in srgb, var(--accent) 30%, transparent);
        }
        .dark-mode .highlight, .dark-mode .gene-info-trigger { color: var(--accent); border-bottom-color: var(--accent); }


        /* References */
        .references-list { list-style-type: none; padding-left: 0; counter-reset: item; }
        .references-list li { margin-bottom: 0.8rem; padding-left: 2.2rem; text-indent: -2.2rem; position: relative; font-size:0.9rem; }
        .references-list li::before { content: '[' counter(item) '] '; counter-increment: item; color: var(--accent); font-weight: bold; }

        /* Pipeline Steps */
        .pipeline-step { margin-bottom: 2rem; padding: 1.5rem; border: 1px solid var(--border-light); border-radius: 8px; background-color: rgba(0,0,0,0.02); }
        .dark-mode .pipeline-step { background-color: rgba(255,255,255,0.03); }
        .pipeline-step h4 { font-size: 1.25rem; margin-bottom: 1rem; }
        .pipeline-step p { font-size: 0.95rem; }
        .pipeline-step img { max-width: 700px; }

        /* Modal for Gene Info and Images */
        .info-modal {
            display: none; position: fixed; z-index: 1001; left: 0; top: 0;
            width: 100%; height: 100%; overflow: auto; background-color: rgba(0,0,0,0.7);
            align-items: center; justify-content: center;
            backdrop-filter: blur(5px);
        }
        .info-modal-content {
            background-color: var(--light-bg); color: var(--text-light);
            margin: auto; padding: 25px; border-radius: 10px;
            width: 90%; max-width: 700px; position: relative;
            box-shadow: 0 10px 30px rgba(0,0,0,0.2);
            max-height: 85vh; overflow-y: auto;
            animation: modal-pop-in 0.4s cubic-bezier(0.175, 0.885, 0.32, 1.275);
        }
        @keyframes modal-pop-in {
            from { transform: scale(0.9) translateY(-20px); opacity: 0; }
            to { transform: scale(1) translateY(0); opacity: 1; }
        }
        .dark-mode .info-modal-content { background-color: var(--dark-bg); color: var(--text-dark); }
        .info-modal-close {
            color: var(--gray); float: right; font-size: 28px; font-weight: bold;
            position: absolute; top: 10px; right: 20px; cursor: pointer;
            transition: color 0.3s, transform 0.3s;
        }
        .info-modal-close:hover, .info-modal-close:focus { color: var(--secondary); text-decoration: none; transform: rotate(90deg); }
        .info-modal h3 { font-family: 'Playfair Display', serif; color: var(--primary); margin-bottom: 1rem; font-size:1.4rem; }
        .info-modal-body p { font-size: 0.95rem; margin-bottom: 0.8rem; }
        .info-modal-body strong { color: var(--primary); }
        .info-modal-image { display: block; max-width: 100%; max-height: 70vh; margin: 1rem auto; border-radius: 8px; }
        .info-modal-figcaption { text-align: center; font-style: italic; color: var(--gray); font-size: 0.9rem; margin-top: 0.5rem; }


        /* Responsive Adjustments */
        @media (max-width: 992px) {
            .navbar { padding: 0.8rem 1rem; }
            .navbar-bottom { flex-direction: column; align-items: stretch; }
            .search-container { width: 100%; margin-bottom: 0.5rem; margin-right: 0; }
            .search-input { width: 100%; }
            .nav-tabs { justify-content: flex-start; }
            .content-container { margin-top: 180px; }
            .institution-header { padding: 1rem; flex-direction: column; }
            .institution-side-logo { height: 100px; margin-bottom: 0.5rem; }
            .institution-text-content { padding: 0; }
        }
        @media (max-width: 768px) {
            .content-section { padding: 1.5rem; }
            .title-page h2 { font-size: 1.6rem; }
            .nav-tabs li { margin: 0.3rem 0.3rem; }
            .nav-tabs a { font-size: 0.85rem; padding: 0.2rem 0.4rem; }
            .content-container { margin-top: 200px; }
            .horizontal-layout { flex-direction: column; }
            .text-content, .figure.inline-figure { flex: 1 1 100%; margin-bottom:1rem; }
            .institution-side-logo { height: 100px; }
        }
         @media (max-width: 576px) {
            .navbar-top { flex-direction: column; align-items: flex-start; }
            .logo { margin-bottom: 0.5rem; }
            .navbar-controls { width: 100%; justify-content: space-between; margin-top: 0.5rem;}
            .language-selector, .dark-mode-toggle, .logout-btn { margin-left: 0.5rem; }
            .content-container { margin-top: 230px; }
             .institution-text-content .institution-line { font-size: 0.9rem; }
             .institution-side-logo { height: 40px; }
        }
        .search-highlight { background-color: yellow; color: black; font-weight: bold; border-radius: 3px; padding: 0 2px; }
        
        /* Contact Section */
        .contact-section { margin-top: 3rem; padding-top: 2rem; border-top: 1px solid var(--border-light); }
        .contact-section h4 { text-align: center; margin-bottom: 1.5rem; font-size: 1.4rem; }
        .contact-grid { display: flex; flex-wrap: wrap; gap: 1.5rem; justify-content: center; }
        .contact-card {
            background-color: color-mix(in srgb, var(--light-bg) 90%, white); 
            border: 1px solid var(--border-light);
            border-radius: 8px; padding: 1.2rem; text-align: center;
            box-shadow: 0 4px 8px var(--shadow-light);
            transition: transform 0.3s ease, box-shadow 0.3s ease;
            flex: 1 1 250px; max-width: 300px;
        }
        .dark-mode .contact-card { background-color: color-mix(in srgb, var(--light-bg) 90%, black); border-color: var(--border-dark); }
        .contact-card:hover {
            transform: translateY(-8px);
            box-shadow: 0 8px 20px color-mix(in srgb, var(--accent) 30%, transparent);
        }
        .contact-name { font-weight: 600; color: var(--primary); font-size: 1.1rem; margin-bottom: 0.5rem; }
        .contact-email { font-size: 0.9rem; color: var(--accent); text-decoration: none; word-break: break-all; }
        .contact-email:hover { text-decoration: underline; color: var(--secondary); }
        
        #dbSchemaImageInitial { max-width: 550px; }
        .info-modal-image { display: block; max-width: 90%; max-height: 75vh; border-radius: 8px; object-fit: contain; }
        
        .work-plan { text-align: left; max-width: 700px; margin: 1.2rem auto; padding: 1.2rem; background: var(--light-bg); border-radius:8px; box-shadow: 0 3px 12px var(--shadow-light); }
        .work-plan h3.work-plan-title {
            font-family: 'Playfair Display', serif; color: var(--primary); 
            margin-bottom: 0.8rem; font-weight: 500; font-size: 1.3rem; text-align:left;
        }
        .work-plan ul.work-plan-list { list-style-type:none; padding-left:0; text-align:center; } 
        .work-plan ul.work-plan-list li {
            margin-bottom: 0.5rem; font-weight: 400; font-size: 0.9rem; 
            padding: 0.2rem 0; border-bottom: 1px dashed var(--border-light);
            display: inline-block;
            text-align: left; width: auto; padding-left: 1.5em; text-indent: -1.5em;
        }
        .work-plan ul.work-plan-list li:last-child { border-bottom: none; }
        
        .interpretation-subtitle {
            font-family: 'Playfair Display', serif; color: var(--primary);
            font-size: 1.15rem; margin-bottom: 0.8rem; margin-top: 1.2rem;
            position: relative; padding-bottom: 0.3rem; font-weight: 600;
        }
        .interpretation-subtitle::after {
            content: ''; position: absolute; bottom: 0; left: 0; width: 35px;
            height: 2.5px; background-color: var(--accent); border-radius: 2px;
        }
        .mutation-block { margin-bottom: 2.5rem; }
        .interpretation-title-section {
            font-family: 'Playfair Display', serif; color: var(--primary);
            font-size: 1.4rem; margin-bottom: 1rem; padding-bottom: 0.5rem;
            border-bottom: 2px solid var(--accent);
        }

    </style>
</head>
<body>
    <!-- Login Overlay -->
    <div class="login-overlay" id="loginScreen">
        <div class="login-container" id="loginContainerForm">
            <h2 class="lang-login-title">Acc√®s au Mini Projet</h2>
            <div class="input-group">
                <input type="text" id="username" placeholder="Nom d'utilisateur" required>
            </div>
            <div class="input-group">
                <input type="password" id="password" placeholder="Mot de passe" required>
            </div>
            <button class="btn lang-login-btn" onclick="login()">Se connecter</button>
        </div>
    </div>

    <!--  Logout Message Overlay -->
    <div class="logout-message-overlay" id="logoutMessageScreen">
        <h2 id="logoutMessageText"></h2>
    </div>

    <!-- Main Content -->
    <div class="main-content" id="mainContent">
        <nav class="navbar">
            <div class="navbar-top">
                <div class="logo">
                    <img src="Logo hor.jpg" alt="Logo Universit√©">
                    <span class="logo-text">UFMC I</span>
                </div>
                <div class="navbar-controls">
                    <button class="dark-mode-toggle" id="darkModeToggle" title="Mode Sombre"><i class="fas fa-moon"></i></button>
                    <div class="language-selector">
                        <button class="language-btn" id="languageBtn" title="Changer de langue">
                            <img src="https://flagcdn.com/w20/fr.png" class="language-flag" id="currentFlag">
                            <span class="language-text-short" id="currentLangText">FR</span>
                            <i class="fas fa-chevron-down" style="font-size: 0.7rem; margin-left: 4px;"></i>
                        </button>
                        <div class="language-dropdown" id="languageDropdownMenu">
                            <div class="language-option" onclick="changeLanguage('fr')"><img src="https://flagcdn.com/w20/fr.png" class="language-flag"> Fran√ßais (FR)</div>
                            <div class="language-option" onclick="changeLanguage('en')"><img src="https://flagcdn.com/w20/gb.png" class="language-flag"> English (EN)</div>
                        </div>
                    </div>
                    <button class="logout-btn" onclick="logout()" title="D√©connexion"><i class="fas fa-sign-out-alt"></i></button>
                </div>
            </div>
            <div class="navbar-bottom">
                <div class="search-container">
                    <i class="fas fa-search search-icon"></i>
                    <input type="text" class="search-input" id="searchInput" placeholder="Rechercher...">
                </div>
                <ul class="nav-tabs" id="navTabs">
                    <li><a href="#home" class="active"><i class="fas fa-home"></i> <span class="lang-home">Accueil</span></a></li>
                    <li><a href="#Introduction"><i class="fas fa-cogs"></i> <span class="lang-matmeth-projet-menu">Introduction</span></a></li>                   
                    <li><a href="#D√©finition"><i class="fas fa-cogs"></i> <span class="lang-matmeth-projet-menu">D√©finition</span></a></li>
                    <li><a href="#pipeline-projet"><i class="fas fa-project-diagram"></i> <span class="lang-pipeline-projet-menu">Pipeline Projet</span></a></li>
                    <li><a href="#conclusion"><i class="fas fa-check-circle"></i> <span class="lang-conclusion-menu">Conclusion</span></a></li>
                    <li><a href="#references"><i class="fas fa-book"></i> <span class="lang-ref-menu">R√©f√©rences</span></a></li>
                </ul>
            </div>
        </nav>

        <div class="content-container">
            <!-- Home Section -->
            <section id="home" class="tab-content active">
                <div class="institution-header">
                    <img src="logo.png" alt="Logo Institution Gauche" class="institution-side-logo"> 
                    <div class="institution-text-content">
                        <div class="institution-line lang-republique">R√©publique Alg√©rienne D√©mocratique et Populaire</div>
                        <div class="institution-line lang-ministere">Minist√®re de l'Enseignement Sup√©rieur et de la Recherche Scientifique</div>
                        <div class="institution-line lang-universite">Universit√© Fr√®res Mentouri Constantine 1</div>
                        <div class="institution-line lang-faculte">Facult√© des Sciences de la Nature et de la Vie</div>
                        <div class="institution-line lang-departement">D√©partement de Biologie Appliqu√©e</div>
                    </div>
                    <img src="logo.png" alt="Logo Institution Droite" class="institution-side-logo"> 
                </div>
                <div class="title-page">
                    <h2 class="lang-title">Analyse Transcriptomique du Cancer du Poumon: Pipeline RNA‚Äëseq complet  (Analyse comparative du transcriptome entre tissus tumoraux et tissus pulmonaires sains).</h2>
                    <div class="authors">
                        <span class="lang-presented">Pr√©sent√© par :</span><br>
                        <strong>Benmeggoura Rahma</strong>
                        <strong>Azara Nourhane</strong>
                    </div>
                    <div class="promo lang-promo">Promo 2026</div>
                </div>
                <div class="content-section work-plan">
                    <h3 class="work-plan-title lang-plan">Plan de Travail</h3>
                    <ul class="styled-list">
                        <li class="lang-plan-generality">Introduction</li>
                        <li class="lang-plan-matmeth">D√©finition</li>
                        <li class="lang-plan-pipeline">Pipeline Projet</li>
                        <li class="lang-plan-conclusion">Conclusion</li>
                        <li class="lang-plan-ref">R√©f√©rences Bibliographiques</li>
                    </ul>
                </div>
            </section>

            <!-- Introduction Section -->
            <section id="intro-generale" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-intro-generale-title">Introduction</h3>
                    <p class="lang-intro-generale-p1">Les cancers familiaux repr√©sentent un ensemble de pathologies canc√©reuses qui apparaissent avec une fr√©quence accrue dans certaines familles en raison de mutations g√©n√©tiques h√©r√©ditaires. Ces mutations, transmises de mani√®re mend√©lienne d'une g√©n√©ration √† l'autre, augmentent significativement le risque de d√©velopper des tumeurs sp√©cifiques.</p>
                    <p class="lang-intro-generale-p2">La compr√©hension des mutations germinales, qui affectent les cellules reproductrices et sont donc pr√©sentes dans toutes les cellules de l'organisme, est essentielle pour la d√©tection pr√©coce, la pr√©vention cibl√©e et le traitement personnalis√© de ces cancers familiaux. Ce projet vise √† mettre en ≈ìuvre un pipeline bioinformatique pour analyser des donn√©es de s√©quen√ßage (l'√©chantillon SRR24002947) afin d'identifier de telles mutations.</p>
                    <div class="table-responsive data-table-container">
                        <table class="data-table">
                            <thead>
                                <tr>
                                    <th class="lang-mutation-table-type">Type de Mutation</th>
                                    <th class="lang-mutation-table-char">Caract√©ristiques</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong class="lang-mutation-table-germ">Mutation Germinale</strong></td>
                                    <td class="lang-mutation-table-germ-desc">Pr√©sente dans les gam√®tes (ovules et spermatozo√Ødes) ‚Üí Transmise √† la descendance ‚Üí Pr√©sente dans toutes les cellules de l'organisme. Peut augmenter le risque de cancer.</td>
                                </tr>
                                <tr>
                                    <td><strong class="lang-mutation-table-som">Mutation Somatique</strong></td>
                                    <td class="lang-mutation-table-som-desc">Acquise au cours de la vie dans une cellule non germinale ‚Üí Non h√©r√©ditaire ‚Üí Affecte uniquement un sous-ensemble de cellules (ex: tumeur). Principale cause des cancers sporadiques.</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </section>

            <!-- D√©finition CF Section -->
            <section id="definition-cf" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-def-cf-title">D√©finition des Cancers Familiaux</h3>
                    <div class="horizontal-layout">
                        <div class="text-content">
                            <p class="lang-def-cf-p1">Les cancers familiaux (ou h√©r√©ditaires) sont des n√©oplasies dont la pr√©disposition g√©n√©tique est h√©rit√©e selon des modalit√©s mend√©liennes. Contrairement aux cancers sporadiques, qui surviennent de mani√®re al√©atoire sous l'influence de facteurs environnementaux et de mutations somatiques acquises, les cancers familiaux sont principalement li√©s √† des mutations constitutionnelles (germinales) transmises verticalement d'une g√©n√©ration √† l'autre.</p>
                            <p class="lang-def-cf-p2">Ces mutations pathog√®nes affectent g√©n√©ralement des g√®nes cl√©s impliqu√©s dans :</p>
                            <ul class="styled-list">
                                <li class="lang-def-cf-li1">La r√©paration des l√©sions de l'ADN (ex: <strong class="gene-info-trigger" data-gene="BRCA1">BRCA1</strong>, <strong class="gene-info-trigger" data-gene="BRCA2">BRCA2</strong>, g√®nes du syst√®me MMR)</li>
                                <li class="lang-def-cf-li2">La r√©gulation du cycle cellulaire (ex: <strong class="gene-info-trigger" data-gene="TP53">TP53</strong>, RB1)</li>
                                <li class="lang-def-cf-li3">Les voies de signalisation intracellulaire (ex: <strong class="gene-info-trigger" data-gene="APC">APC</strong>, <strong class="gene-info-trigger" data-gene="PTEN">PTEN</strong>)</li>
                                <li class="lang-def-cf-li4">L'apoptose (mort cellulaire programm√©e)</li>
                            </ul>
                            <p class="lang-def-cf-p3">La pr√©sence d'une telle mutation ne signifie pas que l'individu d√©veloppera syst√©matiquement un cancer, mais son risque est consid√©rablement accru par rapport √† la population g√©n√©rale.</p>
                        </div>
                        <div class="figure inline-figure">
                             <img src="image 1.jpg" alt="M√©canismes mol√©culaires cancers familiaux" onclick="openInfoModal('image 1.jpg', 'Figure 01: M√©canismes mol√©culaires impliqu√©s dans les cancers familiaux')"> 
                            <div class="figure-caption lang-fig1cf">Figure 01: M√©canismes mol√©culaires impliqu√©s dans les cancers familiaux. </div>
                        </div>
                    </div>
                </div>
            </section>

            <!-- Types CF Section -->
            <section id="types-cf" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-types-cf-title">Principaux Types de Syndromes de Cancers Familiaux</h3>
                    <h4 class="lang-types-cf-h4-1">1. Syndrome Seins-Ovaires H√©r√©ditaire</h4>
                    <p class="lang-types-cf-p1">Principalement d√ª √† des mutations des g√®nes <strong class="gene-info-trigger" data-gene="BRCA1">BRCA1</strong> et <strong class="gene-info-trigger" data-gene="BRCA2">BRCA2</strong>, impliqu√©s dans la r√©paration de l'ADN. Augmente consid√©rablement le risque de :</p>
                    <ul class="styled-list">
                        <li class="lang-types-cf-li1">40-85% de risque de cancer du sein (vs 12% en population g√©n√©rale)</li>
                        <li class="lang-types-cf-li2">10-40% de risque de cancer de l'ovaire (vs 1-2%)</li>
                        <li class="lang-types-cf-li3">Repr√©sentent 5-10% des cancers du sein et 15% des cancers ovariens</li>
                    </ul>
                    <h4 class="lang-types-cf-h4-2">2. Cancer Colorectal H√©r√©ditaire</h4>
                    <p class="lang-types-cf-p2">Principalement associ√© √† :</p>
                    <ul class="styled-list">
                        <li class="lang-types-cf-lynch">Syndrome de Lynch (g√®nes <strong class="gene-info-trigger" data-gene="MLH1">MLH1</strong>, <strong class="gene-info-trigger" data-gene="MSH2">MSH2</strong>, <strong class="gene-info-trigger" data-gene="MSH6">MSH6</strong>, PMS2)</li>
                        <li class="lang-types-cf-paf">Polypose ad√©nomateuse familiale (g√®ne <strong class="gene-info-trigger" data-gene="APC">APC</strong>)</li>
                        <li class="lang-types-cf-li4">Risque cumulatif √† 70 ans : 50-80% (vs 5% en population g√©n√©rale)</li>
                    </ul>
                    <h4 class="lang-types-cf-h4-prostate">3. Cancer de la Prostate Familial</h4>
                    <p class="lang-types-cf-p3">Associ√© notamment aux mutations :</p>
                    <ul class="styled-list">
                        <li class="lang-types-cf-li5"><strong class="gene-info-trigger" data-gene="BRCA2">BRCA2</strong> (risque augment√© de 5 √† 8 fois)</li>
                        <li class="lang-types-cf-li6">HOXB13</li>
                        <li class="lang-types-cf-li7">ATM, CHEK2</li>
                    </ul>
                    <h4 class="lang-types-cf-h4-lynchdetail">4. Syndrome de Lynch (d√©tail)</h4>
                    <p class="lang-types-cf-p4">Augmente le risque de :</p>
                    <ul class="styled-list">
                        <li class="lang-types-cf-li8">Cancer de l'endom√®tre (40-60% de risque)</li>
                        <li class="lang-types-cf-li9">Cancer de l'ovaire (10-12%)</li>
                        <li class="lang-types-cf-li10">Autres cancers (estomac, intestin gr√™le, voies urinaires)</li>
                    </ul>
                    <div class="image-gallery">
                        <a href="image 2.jpg" data-lightbox="gallery-types" data-title="Figure 02: Illustration Cancer du Sein"><img src="image 2.jpg" alt="Cancer du sein"></a>
                        <a href="image 3.jpg" data-lightbox="gallery-types" data-title="Figure 03: Illustration Polypes Colorectaux"><img src="image 3.jpg" alt="Polypes"></a>
                        <a href="image 4.jpg" data-lightbox="gallery-types" data-title="Figure 04: Structure G√®ne BRCA (Exemple)"><img src="image 4.jpg" alt="G√®ne BRCA"></a>
                        <a href="image 5.jpg" data-lightbox="gallery-types" data-title="Figure 05: Pedigree Cancer Familial"><img src="image 5.jpg" alt="Pedigree"></a>
                    </div>
                </div>
            </section>

            <!-- Facteurs CF Section -->
            <section id="facteurs-cf" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-factors-cf-title">Facteurs de Risque des Cancers Familiaux</h3>
                    <ul class="styled-list">
                        <li class="lang-factors-cf-li1"><strong>Ant√©c√©dents familiaux :</strong> Occurrence de cancers similaires chez plusieurs apparent√©s au 1<sup>er</sup> degr√© (parents, fratrie, enfants)</li>
                        <li class="lang-factors-cf-li2"><strong>Mutations constitutionnelles :</strong> Alt√©rations pathog√®nes dans des g√®nes de pr√©disposition (<strong class="gene-info-trigger" data-gene="BRCA1">BRCA1</strong>/<strong class="gene-info-trigger" data-gene="BRCA2">BRCA2</strong>, <strong class="gene-info-trigger" data-gene="APC">APC</strong>, <strong class="gene-info-trigger" data-gene="MLH1">MLH1</strong>/<strong class="gene-info-trigger" data-gene="MSH2">MSH2</strong>, etc.)</li>
                        <li class="lang-factors-cf-li3"><strong>√Çge de survenue pr√©coce :</strong> Apparition des tumeurs √† un √¢ge significativement plus jeune que la moyenne</li>
                        <li class="lang-factors-cf-li4"><strong>Ph√©notype particulier :</strong> Multiplicit√© des tumeurs, localisations sp√©cifiques, associations syndromiques</li>
                        <li class="lang-factors-cf-li5"><strong>Facteurs √©pig√©n√©tiques :</strong> Modifications de l'expression g√©nique sans alt√©ration de la s√©quence d'ADN</li>
                        <li class="lang-factors-cf-li6"><strong>Interactions g√®ne-environnement :</strong> Potentialisation des risques par des facteurs externes (tabac, alcool, rayonnements)</li>
                    </ul>
                </div>
            </section>

            <!-- Sympt√¥mes CF Section -->
            <section id="symptomes-cf" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-symptoms-cf-title">Manifestations Cliniques</h3>
                    <h4 class="lang-symptoms-cf-h4-sein">Cancer du Sein</h4>
                    <ul class="styled-list">
                        <li class="lang-symptoms-cf-sein1">Nodule palpable indolore</li>
                        <li class="lang-symptoms-cf-sein2">Modifications cutan√©es (peau d'orange, r√©traction)</li>
                        <li class="lang-symptoms-cf-sein3">√âcoulement mamelonnaire</li>
                        <li class="lang-symptoms-cf-sein4">Ad√©nopathies axillaires</li>
                    </ul>
                    <h4 class="lang-symptoms-cf-h4-colo">Cancer Colorectal</h4>
                    <ul class="styled-list">
                        <li class="lang-symptoms-cf-colo1">Rectorragies (saignements rectaux)</li>
                        <li class="lang-symptoms-cf-colo2">Alt√©ration du transit intestinal (diarrh√©e/constipation)</li>
                        <li class="lang-symptoms-cf-colo3">Douleurs abdominales persistantes</li>
                        <li class="lang-symptoms-cf-colo4">An√©mie ferriprive inexpliqu√©e</li>
                    </ul>
                    <h4 class="lang-symptoms-cf-h4-pros">Cancer de la Prostate</h4>
                    <ul class="styled-list">
                        <li class="lang-symptoms-cf-pros1">Dysurie (difficult√© √† uriner)</li>
                        <li class="lang-symptoms-cf-pros2">Pollakiurie (mictions fr√©quentes)</li>
                        <li class="lang-symptoms-cf-pros3">H√©maturie (sang dans les urines)</li>
                        <li class="lang-symptoms-cf-pros4">Douleurs pelviennes ou lombaires</li>
                    </ul>
                    <h4 class="lang-symptoms-cf-h4-ova">Cancer de l'Ovaire</h4>
                    <ul class="styled-list">
                        <li class="lang-symptoms-cf-ova1">M√©t√©orisme abdominal (ballonnements)</li>
                        <li class="lang-symptoms-cf-ova2">Douleurs pelviennes chroniques</li>
                        <li class="lang-symptoms-cf-ova3">Troubles digestifs non sp√©cifiques</li>
                        <li class="lang-symptoms-cf-ova4">Augmentation du volume abdominal</li>
                    </ul>
                </div>
            </section>

            <!-- Stades CF Section -->
            <section id="stades-cf" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-stages-cf-title">Stadification des Cancers</h3>
                    <p class="lang-stages-cf-p1">La classification TNM (Tumeur, Node, Metastasis) est utilis√©e pour √©valuer l'extension des cancers familiaux, comme pour les formes sporadiques :</p>
                    <div class="table-responsive data-table-container">
                        <table class="data-table">
                            <thead>
                                <tr>
                                    <th class="lang-stages-table-stade">Stade</th>
                                    <th class="lang-stages-table-carac">Caract√©ristiques</th>
                                    <th class="lang-stages-table-prog">Pronostic</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr><td><strong class="lang-stages-cf-s1">Stade I</strong></td><td class="lang-stages-cf-s1d">Tumeur localis√©e, limit√©e au tissu d'origine</td><td class="lang-stages-cf-s1p">Excellent (survie >90% √† 5 ans)</td></tr>
                                <tr><td><strong class="lang-stages-cf-s2">Stade II</strong></td><td class="lang-stages-cf-s2d">Extension locale aux tissus adjacents</td><td class="lang-stages-cf-s2p">Bon (survie 70-90%)</td></tr>
                                <tr><td><strong class="lang-stages-cf-s3">Stade III</strong></td><td class="lang-stages-cf-s3d">Atteinte des ganglions lymphatiques r√©gionaux</td><td class="lang-stages-cf-s3p">Interm√©diaire (survie 30-70%)</td></tr>
                                <tr><td><strong class="lang-stages-cf-s4">Stade IV</strong></td><td class="lang-stages-cf-s4d">M√©tastases √† distance (foie, poumon, os, etc.)</td><td class="lang-stages-cf-s4p">R√©serv√© (survie <30%)</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </section>

            <!-- Mat√©riel et M√©thodes Projet Section -->
            <section id="materiel-methodes-projet" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-matmeth-projet-title">Mat√©riel et M√©thodes</h3>

                    <h4 class="lang-matmeth-data-and-setup">Donn√©es, G√©nome de R√©f√©rence et Plateforme d'Analyse Principale</h4>
                    <ul class="styled-list">
                        <li><strong class="lang-matmeth-projet-data">Donn√©es Utilis√©es :</strong>
                            <ul style="margin-top: 0.5rem; margin-left: 1rem;">
                                <li class="lang-matmeth-projet-sample">√âchantillon : <a href="https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947" target="_blank" rel="noopener noreferrer">SRR24002947</a> (accessible sur NCBI SRA).</li>
                                <li class="lang-matmeth-projet-type">Type de donn√©es : S√©quen√ßage du G√©nome Entier (Whole Genome Sequencing - WGS).</li>
                                <li class="lang-matmeth-projet-origin">Origine : √âchantillon de sang d'un patient p√©diatrique (√©tude Gr√∂bner et al., Nature 2018).</li>
                            </ul>
                        </li>
                        <li><strong class="lang-matmeth-projet-refgenome">G√©nome de R√©f√©rence :</strong> <span class="highlight lang-matmeth-projet-refgenomeval">GRCh38/hg38</span>.</li>
                        <li><strong class="lang-matmeth-projet-mainplatform">Plateforme d'Analyse Principale :</strong> <a href="https://usegalaxy.eu/" target="_blank" rel="noopener noreferrer">UseGalaxy.eu</a> (utilis√©e pour la r√©alisation du pipeline principal).</li>
                    </ul>

                    <h4 class="lang-matmeth-software-resources">Logiciels et Ressources en Ligne Utilis√©s</h4>
                    <p class="lang-matmeth-software-intro">
                        Pour mener √† bien ce projet, divers logiciels, plateformes d'analyse et bases de donn√©es ont √©t√© employ√©s :
                    </p>
                    <ul class="styled-list">
                        <li><a href="https://usegalaxy.eu/" target="_blank" rel="noopener noreferrer"><strong>UseGalaxy.eu</strong></a> : Plateforme principale pour l'ex√©cution du pipeline bioinformatique (contr√¥le qualit√©, alignement, appel de variants).</li>
                        <li><a href="https://usegalaxy.org/" target="_blank" rel="noopener noreferrer"><strong>UseGalaxy.org</strong></a> : Plateforme alternative ou compl√©mentaire pour certains outils bioinformatiques.</li>
                        <li><a href="https://www.ncbi.nlm.nih.gov/" target="_blank" rel="noopener noreferrer"><strong>NCBI (National Center for Biotechnology Information)</strong></a> : Pour l'acc√®s aux donn√©es de s√©quen√ßage (SRA), aux informations sur les g√®nes et les variants.</li>
                        <li><a href="https://mutalyzer.nl/" target="_blank" rel="noopener noreferrer"><strong>Mutalyzer 3</strong></a> : Pour la v√©rification et la standardisation de la nomenclature HGVS des variants g√©n√©tiques identifi√©s.</li>
                        <li><a href="https://www.ensembl.org/info/docs/tools/vep/index.html" target="_blank" rel="noopener noreferrer"><strong>VEP (Variant Effect Predictor - Ensembl)</strong></a> : Outil d'annotation pour pr√©dire les effets fonctionnels des variants g√©nomiques.</li>
                        <li><a href="https://www.ncbi.nlm.nih.gov/clinvar/" target="_blank" rel="noopener noreferrer"><strong>ClinVar</strong></a> : Base de donn√©es archivant les relations entre les variations g√©n√©tiques humaines et les ph√©notypes observ√©s, cruciale pour l'interpr√©tation clinique.</li>
                        <li><a href="https://www.easyphp.org/" target="_blank" rel="noopener noreferrer"><strong>EasyPHP</strong></a> : Utilis√© pour cr√©er la base de donn√©es du projet.</li>
                        <li><a href="https://chat.openai.com/" target="_blank" rel="noopener noreferrer"><strong>ChatGPT (OpenAI)</strong></a> : Outil d'assistance pour la r√©daction, la structuration d'id√©es et la g√©n√©ration de contenu textuel.</li>
                        <li><a href="https://gemini.google.com/" target="_blank" rel="noopener noreferrer"><strong>Gemini (Google)</strong></a> : Outil d'assistance pour la recherche d'informations, la g√©n√©ration de code et la r√©solution de probl√®mes techniques.</li>
                    </ul>

                    <h4 class="lang-matmeth-configpc">Configurations des Postes de Travail Utilis√©s :</h4>
                    <div class="table-responsive data-table-container">
                        <table class="data-table">
                            <thead>
                                <tr>
                                    <th class="lang-configpc-poste">Poste</th>
                                    <th class="lang-configpc-carac">Caract√©ristique</th>
                                    <th class="lang-configpc-val">Valeur</th>
                                </tr>
                            </thead>
                            <tbody>
                                <!-- PC 01 -->
                                <tr><td rowspan="6" style="font-weight:bold; vertical-align: middle; text-align:center;">PC 01</td><td class="lang-configpc-devname">Nom de l'appareil</td><td>DESKTOP-VRCV5HR</td></tr>
                                <tr><td class="lang-configpc-proc">Processeur</td><td>11th Gen Intel(R) Core(TM) i5-1135G7 @ 2.40GHz   2.42 GHz</td></tr>
                                <tr><td class="lang-configpc-ram">M√©moire RAM install√©e</td><td>8,00 Go (7,73 Go utilisable)</td></tr>
                                <tr><td class="lang-configpc-systype">Type du syst√®me</td><td>Syst√®me d‚Äôexploitation 64 bits, processeur x64</td></tr>
                                <tr><td class="lang-configpc-winedition">√âdition Windows</td><td>Windows 11 Professionnel</td></tr>
                                <tr><td class="lang-configpc-winver">Version Windows</td><td>24H2</td></tr>
                                <!-- PC 02 -->
                                <tr><td rowspan="8" style="font-weight:bold; vertical-align: middle; text-align:center;">PC 02</td><td class="lang-configpc-devname">Nom de l'appareil</td><td>DESKTOP-CTS2KBI</td></tr>
                                <tr><td class="lang-configpc-proc">Processeur</td><td>11th Gen Intel(R) Core(TM) i3-1115G4 @ 3.00GHz   3.00 GHz</td></tr>
                                <tr><td class="lang-configpc-ram">M√©moire RAM install√©e</td><td>4,00 Go (3,81 Go utilisable)</td></tr>
                                <tr><td class="lang-configpc-systype">Type du syst√®me</td><td>Syst√®me d‚Äôexploitation 64 bits, processeur x64</td></tr>
                                <tr><td class="lang-configpc-winedition">√âdition Windows</td><td>Windows 11 Professionnel</td></tr>
                                <tr><td class="lang-configpc-winver">Version Windows</td><td>24H2</td></tr>
                                <tr><td class="lang-configpc-installdate">Install√© le</td><td>20/04/2025</td></tr>
                                <tr><td class="lang-configpc-build">Build du syst√®me d‚Äôexploitation</td><td>26100.4061</td></tr>
                                <!-- PC 03  -->
                                <tr><td rowspan="8" style="font-weight:bold; vertical-align: middle; text-align:center;">PC 03</td><td class="lang-configpc-devname">Nom de l'appareil</td><td>DESKTOP-DNUS3VE</td></tr>
                                <tr><td class="lang-configpc-proc">Processeur</td><td>Intel(R) Core(TM) i3-7020U CPU @ 2.30GHz   2.30 GHz</td></tr>
                                <tr><td class="lang-configpc-ram">M√©moire RAM install√©e</td><td>4,00 Go (3,87 Go utilisable)</td></tr>
                                <tr><td class="lang-configpc-systype">Type du syst√®me</td><td>Syst√®me d‚Äôexploitation 64 bits, processeur x64</td></tr>
                                <tr><td class="lang-configpc-winedition">√âdition Windows</td><td>Windows 10 Professionnel</td></tr>
                                <tr><td class="lang-configpc-winver">Version Windows</td><td>22H2</td></tr>
                                <tr><td class="lang-configpc-installdate">Install√© le (derni√®re info)</td><td>16/12/2024</td></tr>
                                <tr><td class="lang-configpc-build">Build du syst√®me d‚Äôexploitation (derni√®re info)</td><td>26100.4061</td></tr>
                                <!-- PC 04 (distinct) -->
                                <tr><td rowspan="8" style="font-weight:bold; vertical-align: middle; text-align:center;">PC 04</td><td class="lang-configpc-devname">Nom de l'appareil</td><td>DESKTOP-BU2GUNV</td></tr>
                                <tr><td class="lang-configpc-proc">Processeur</td><td>Intel(R) Celeron(R) CPU N3350 @ 1.10GHz   1.10 GHz</td></tr>
                                <tr><td class="lang-configpc-ram">M√©moire RAM install√©e</td><td>6,00 Go (5,83 Go utilisable)</td></tr>
                                <tr><td class="lang-configpc-systype">Type du syst√®me</td><td>Syst√®me d‚Äôexploitation 64 bits, processeur x64</td></tr>
                                <tr><td class="lang-configpc-winedition">√âdition Windows</td><td>Windows 10 Professionnel</td></tr>
                                <tr><td class="lang-configpc-winver">Version Windows</td><td>22H2</td></tr>
                                <tr><td class="lang-configpc-installdate">Install√© le</td><td>19/05/2025</td></tr>
                                <tr><td class="lang-configpc-build">Build du syst√®me d‚Äôexploitation</td><td>19045.5854</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </section>

            <!-- Pipeline Projet Section -->
            <section id="pipeline-projet" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-pipeline-whatis">Un pipeline Bioinformatique</h3>
                    <p class="lang-pipeline-whatis-desc"> Un pipeline bioinformatique est une suite structur√©e d‚Äô√©tapes ou d‚Äôoutils utilis√©s pour traiter, analyser et interpr√©ter des donn√©es biologiques, souvent de mani√®re automatis√©e.
                    Dans le cas des donn√©es de s√©quen√ßage, un pipeline permet de passer d‚Äôun fichier brut (comme un fichier FASTQ) jusqu‚Äô√† l‚Äôidentification et l‚Äôannotation de variants g√©n√©tiques, √† travers des √©tapes comme le contr√¥le qualit√©, le nettoyage, l‚Äôalignement, et l‚Äôappel de variants.</p>

                    <h3 class="lang-pipeline-objective-title">Objectif du Projet</h3>
                    <p class="lang-pipeline-objective-p1">L'objectif principal de ce projet est de d√©velopper et d'appliquer un pipeline bioinformatique rigoureux pour l'analyse de donn√©es de s√©quen√ßage du g√©nome. En utilisant l'√©chantillon public SRR24002947 comme √©tude de cas, nous visons √† identifier, annoter et interpr√©ter les mutations germinales, c'est-√†-dire les alt√©rations g√©n√©tiques h√©r√©ditaires, qui pourraient √™tre impliqu√©es dans la pr√©disposition aux cancers familiaux. Ce travail illustre les √©tapes cl√©s allant du traitement des donn√©es brutes de s√©quen√ßage √† l'√©valuation de l'impact potentiel des variants g√©n√©tiques d√©couverts, notamment sur des g√®nes d'int√©r√™t majeur comme BRCA1 et BRCA2. √Ä travers cette d√©marche, nous cherchons √† d√©montrer l'apport concret de la bioinformatique dans la compr√©hension des bases g√©n√©tiques des maladies h√©r√©ditaires et √† pr√©senter ce processus complexe de mani√®re claire et interactive via cette plateforme web.</p>
                    <h3 class="lang-pipeline-projet-title">Description du Pipeline Bioinformatique R√©alis√© sur Galaxy</h3>
                    <p class="lang-pipeline-intro-srr">Pour illustrer concr√®tement l'analyse des mutations germinales dans les cancers familiaux, notre travail s'est concentr√© sur l'√©chantillon public <a href="https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947" target="_blank" rel="noopener noreferrer"><strong>SRR24002947</strong></a>. Cet √©chantillon est issu du projet de recherche <a href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA949945" target="_blank" rel="noopener noreferrer"><strong>PRJNA949945</strong></a>, une √©tude d√©di√©e √† la caract√©risation du profil des mutations germinales des g√®nes cruciaux <strong>BRCA1 et BRCA2</strong> au sein de la population marocaine atteinte de cancer du sein. Comme le souligne cette √©tude, le cancer du sein est une pathologie majeure, et environ 20% des cas pr√©sentent une composante h√©r√©ditaire o√π les mutations de BRCA1/2 jouent un r√¥le pr√©pond√©rant. L'identification des porteurs de telles mutations est donc essentielle non seulement pour la pr√©vention et la d√©tection pr√©coce, mais aussi pour orienter vers une m√©decine personnalis√©e et des strat√©gies de chimiopr√©vention adapt√©es. L'objectif de l'√©tude PRJNA949945 est ainsi d'approfondir les connaissances sur les facteurs de risque g√©n√©tiques sp√©cifiques au Maroc.</p>
                    <p class="lang-pipeline-intro-tech">Les donn√©es de l'√©chantillon SRR24002947 ont √©t√© g√©n√©r√©es gr√¢ce √† des techniques de <strong>s√©quen√ßage de nouvelle g√©n√©ration (NGS)</strong>, plus pr√©cis√©ment par s√©quen√ßage <strong>Ion Torrent Proton</strong>. Cette approche a utilis√© le panel cibl√© <strong>Oncomine BRCA1 et BRCA2</strong> sur de l'ADN g√©nomique humain, suivant une strat√©gie de s√©quen√ßage d'amplicons (layout SINGLE). Il est √† noter que l'assemblage de r√©f√©rence initialement associ√© √† ces donn√©es sur SRA est <strong>GRCh37</strong>.</p>
                    <p class="lang-pipeline-intro-analysis">Notre pipeline bioinformatique, que nous avons impl√©ment√© sur la plateforme <strong>UseGalaxy.eu</strong>, a √©t√© con√ßu pour traiter ces donn√©es brutes. Pour notre analyse, nous avons align√© les lectures sur la version <strong>GRCh38/hg38</strong> du g√©nome de r√©f√©rence humain, afin d'identifier les variants potentiels au sein des s√©quences des g√®nes BRCA1 et BRCA2. Ces variants ont ensuite √©t√© annot√©s en utilisant des bases de donn√©es comme ClinVar et des outils comme Mutalyzer pour √©valuer leur pathog√©nicit√© √©ventuelle. Les √©tapes d√©taill√©es de ce pipeline sont d√©crites ci-dessous :</p>

                    <div class="pipeline-step">
                        <h4 class="lang-pipeline-step1-title">1. Contr√¥le Qualit√© Initial des Lectures Brutes</h4>
                        <p><strong class="lang-pipeline-step-tool">Outil Galaxy :</strong> FastQC.</p>
                        <p><strong class="lang-pipeline-step-obj">Objectif :</strong> √âvaluer la qualit√© initiale des s√©quences du fichier <code>SRR24002947.fastq.gz</code>.</p>
                        <a href="SRR24002947_fastq_gz_fastqc.html" target="_blank"><img align="center" src="fastqc_rapport.png" alt="FastQC initial SRR24002947" onclick="openInfoModal('fastqc_rapport.png', 'Figure: Rapport FastQC initial pour SRR24002947.')"></a> 
                        <div class="figure-caption lang-pipeline-step1-cap">Figure: Rapport FastQC initial. </div>
                    </div>
                    <div class="pipeline-step">
                        <h4 class="lang-pipeline-step2-title">2. Nettoyage des Lectures (Trimmomatic)</h4>
                        <p><strong class="lang-pipeline-step-tool">Outil Galaxy :</strong> Trimmomatic.</p>
                        <p><strong class="lang-pipeline-step-obj">Objectif :</strong> Supprimer les adaptateurs et les bases de faible qualit√©.</p>
                    </div>
                     <div class="pipeline-step">
                        <h4 class="lang-pipeline-step3-title">3. Contr√¥le qualit√© apr√®s nettoyage</h4>
                        <p><strong class="lang-pipeline-step-tool">Outil Galaxy :</strong> FastQC.</p>
                        <p><strong class="lang-pipeline-step-obj">Objectif :</strong>V√©rifier l'am√©lioration de la qualit√© des s√©quences apr√®s le trimming.</p>
                        <a href="FATQC apr√©s nettoyage2.html" target="_blank"><img src="FATQC apr√©s nettoyage.png" alt="FastQC apr√®s Trimmomatic" onclick="openInfoModal('FATQC apr√©s nettoyage.png', 'Figure: Rapport FastQC apr√®s Trimmomatic.')"></a> 
                        <div class="figure-caption lang-pipeline-step3-cap">Figure: Rapport FastQC apr√®s nettoyage.</div>
                    </div>
                    <div class="pipeline-step">
                        <h4 class="lang-pipeline-step4-title">4. Alignement sur le g√©nome de r√©f√©rence</h4>
                        <p><strong class="lang-pipeline-step-tool">Outil Galaxy :</strong> Bowtie2.</p>
                        <p><strong class="lang-pipeline-step-obj">Objectif :</strong> Aligner les lectures nettoy√©es sur GRCh38.</p>
                        <img src="Botie2 IMG.png" alt="Alignement Bowtie2" onclick="openInfoModal('Botie2 IMG.png', 'Figure: Options Alignement Bowtie2.')"> 
                    </div>
                    <div class="pipeline-step">
                        <h4 class="lang-pipeline-step5-title">5. Traitement du fichier BAM</h4>
                        <p><strong class="lang-pipeline-step-tool">Outils Galaxy :</strong> Samtools view, sort; Picard MarkDuplicates.</p>
                        <p><strong class="lang-pipeline-step-obj">Objectif :</strong> Convertir, trier, marquer les duplicats.</p>
                        <img src="MarkDuplicates.png" alt="Samtools MarkDuplicates" onclick="openInfoModal('MarkDuplicates.png', 'Figure: Options Marquage Duplicats Picard.')"> 
                    </div>
                    <div class="pipeline-step">
                        <h4 class="lang-pipeline-step6-title">6. Appel des variants</h4>
                        <p><strong class="lang-pipeline-step-tool">Outils Galaxy :</strong> Bcftools mpileup, Freebayes.</p>
                        <p><strong class="lang-pipeline-step-obj">Objectif :</strong> Identifier les mutations germinales (VCF).</p>
                    </div>
                     <div class="pipeline-step">
                        <h4 class="lang-pipeline-step7-title">7. Annotation des variants avec SnpEff</h4>
                        <p><strong class="lang-pipeline-step-tool">Outil Galaxy :</strong> SnpEff.</p>
                        <p><strong class="lang-pipeline-step-obj">Objectif :</strong> Pr√©dire l'effet fonctionnel des variants.</p>
                        <a href="SnpEff_eff.html" target="_blank"><img src="SnpEff_eff..png" alt="Rapport SnpEff" onclick="openInfoModal('SnpEff_eff..png', 'Figure: Rapport SnpEff.')"></a> 
                        <div class="figure-caption lang-pipeline-step7-cap">Figure: Rapport SnpEff_eff.</div>
                    </div>
                    <div class="pipeline-step">
                         <h4 class="lang-pipeline-step8-title">üìä 8. Sch√©ma R√©capitulatif du Pipeline sur Galaxy</h4>
                         <p class="lang-pipeline-step8-p1">Workflow global impl√©ment√© dans Galaxy :</p>
                         <a href="https://usegalaxy.eu/u/25ouail06/h/unnamed-history-1" target="_blank" rel="noopener noreferrer">
                         <img src="Workflow Pipeline.png" alt="Sch√©ma du pipeline Galaxy pour SRR24002947" onclick="openInfoModal('Workflow Pipeline.png', 'Figure: Workflow Galaxy utilis√© pour l\'analyse de SRR24002947.')">
                          </a>
                       <div class="figure-caption lang-pipeline-step8-cap">Figure: Workflow Galaxy utilis√©.</div>
                     </div>

                    <h4 class="lang-pipeline-resultats-title">R√©sultats de l'Analyse de SRR24002947</h4>
                    <h5 class="lang-pipeline-resultats-stats">Statistiques du Pipeline :</h5>
                    <ul class="styled-list">
                       
                        <li class="lang-pipeline-stat-raw">Nombre total de lectures brutes : 3,675,752 </li>
                        <li class="lang-pipeline-stat-clean">Nombre de lectures apr√®s nettoyage : <strong>3,670,123</strong></li>
                        <li class="lang-pipeline-stat-align">Taux d'alignement : <strong>99.85%</strong></li>
                        <li class="lang-pipeline-stat-varraw">Nombre de variants bruts : <strong>25</strong></li>
                        <li class="lang-pipeline-stat-varfilt">Nombre de variants apr√®s filtration : <strong>25</strong></li>
                        <li class="lang-pipeline-stat-varclinvar">Nombre de variants ClinVar (Pathogenic/Likely Pathogenic) : <strong>2</strong></li>
                    </ul>
                    <h5 class="lang-pipeline-resultats-muttable">Tableau des Mutations d'Int√©r√™t Identifi√©es :</h5>
                    <div class="table-responsive data-table-container">
                        <table class="data-table">
                            <thead>
                                <tr>
                                    <th class="lang-muttable-chr">Chr</th><th class="lang-muttable-pos">Pos (GRCh38)</th>
                                    <th class="lang-muttable-gene">G√®ne</th><th class="lang-muttable-eff">Effet Pr√©dit</th><th class="lang-muttable-hgvsc">HGVS (c.)</th>
                                    <th class="lang-muttable-hgvsp">HGVS (p.)</th><th class="lang-muttable-clnsig">Signification Clinique</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>chr17</td><td>43124029</td>
                                    <td>BRCA1</td><td>missense_variant</td><td>c.116G>A</td>
                                    <td>p.Cys39Tyr</td>
                                    <td>Pathogenic / Likely Pathogenic</td>
                                </tr>
                                <tr>
                                    <td>chr13</td><td>32339502</td>
                                    <td>BRCA2</td><td>frameshift_variant</td><td>c.728del</td>
                                    <td>p.Ser243IlefsTer5</td>
                                    <td>Pathogenic</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                     <p class="lang-pipeline-resultats-note">
                        Note : Les positions et nomenclatures sont bas√©es sur GRCh38 et les transcrits de r√©f√©rence (NM_007294.4 pour BRCA1, NM_000059.4 pour BRCA2).
                    </p>
                    
                    <!-- VEP SECTION -->
                    <h4 class="lang-vep-title">Annotation Compl√©mentaire avec VEP</h4>
                    <p class="lang-vep-desc">Pour une meilleure  annotation et pour corroborer les r√©sultats , nous avons utilis√© le Variant Effect Predictor (VEP) d'Ensembl comme outil externe √† Galaxy. VEP fournit une analyse d√©taill√©e des cons√©quences des variants sur les g√®nes, transcrits, et prot√©ines, en s'appuyant sur un large √©ventail de sources de donn√©es, ce qui enrichit l'interpr√©tation de leur impact potentiel.</p>
                    <div class="image-gallery" style="justify-content: center; gap: 25px; scroll-snap-type: none;">
                        <a href="https://www.ensembl.org/Homo_sapiens/Tools/VEP" target="_blank" rel="noopener noreferrer">
                            <img src="VEP 01.jpg" alt="" style="height: 200px; width: auto; border:1px solid var(--border-light); object-fit: contain;">
                            <div class="figure-caption lang-vep-caption-1" style="text-align: center;">.</div>
                        </a>
                        <a href="https://usegalaxy.org/" target="_blank" rel="noopener noreferrer">
                            <img src="VEP 02.jpg" alt="" style="height: 200px; width: auto; border:1px solid var(--border-light); object-fit: contain;">
                            <div class="figure-caption lang-vep-caption-2" style="text-align: center;">.</div>
                        </a>
                        <a href="https://www.ensembl.org/Homo_sapiens/Tools/VEP" target="_blank" rel="noopener noreferrer">
                            <img src="VEP 03.jpg" alt="Visualisation VEP 3" style="height: 200px; width: auto; border:1px solid var(--border-light); object-fit: contain;">
                            <div class="figure-caption lang-vep-caption-3" style="text-align: center;">.</div>
                        </a>
                    </div>
                </div>
            </section>
                    <!-- Int√©rpr√©tation SECTION -->
            <section id="interpretation-projet" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-interpretation-main-title">Interpr√©tation des Variants G√©n√©tiques</h3>

                    <p class="lang-interpretation-method-intro">
                        L'identification de variants g√©n√©tiques par s√©quen√ßage de nouvelle g√©n√©ration (NGS) n'est que la premi√®re √©tape d'une analyse complexe. Le d√©fi majeur r√©side dans l'interpr√©tation de ces variants afin de d√©terminer leur pertinence clinique, notamment dans le contexte des maladies h√©r√©ditaires comme les cancers familiaux. Ce processus implique l'utilisation d'outils bioinformatiques pour pr√©dire l'effet fonctionnel des mutations sur les g√®nes et les prot√©ines (par exemple, via VEP/SnpEff), la standardisation de leur nomenclature (avec des outils comme Mutalyzer), et leur comparaison avec des bases de donn√©es cliniques exhaustives (telles que ClinVar) qui recensent les variants connus et leur association avec des ph√©notypes.
                    </p>
                    <p class="lang-interpretation-project-focus">
                        Dans le cadre de ce projet, apr√®s l'application de notre pipeline bioinformatique sur l'√©chantillon SRR24002947, nous avons proc√©d√© √† cette d√©marche d'interpr√©tation pour les variants identifi√©s. Nous illustrons ci-dessous ce processus avec les mutations notables issues de notre analyse (<strong class="highlight">BRCA1 c.116G>A</strong> et <strong class="highlight">BRCA2 c.728del</strong>), ainsi que d'autres exemples de mutations fr√©quemment impliqu√©es dans les syndromes de pr√©disposition au cancer.
                    </p>

                    <div class="mutation-block">
                        <h4 class="interpretation-title-section lang-mut-brca1-c116-title">
                            Variant de l'√âchantillon : G√®ne <span class="gene-info-trigger" data-gene="BRCA1">BRCA1</span> - <span class="highlight">NM_007294.4:c.116G>A</span>
                        </h4>
                        <h5 class="interpretation-subtitle lang-mut-brca1-c116-def-title">D√©finition de la mutation</h5>
                        <div class="horizontal-layout" style="margin-bottom: 1.5rem; align-items: flex-start;">
                            <div class="text-content" style="flex-basis: 65%;">
                                <p class="lang-mut-brca1-c116-def-p1">
                                    La mutation √©tudi√©e est <strong class="highlight">NM_007294.4:c.116G>A</strong> dans le g√®ne <strong class="gene-info-trigger" data-gene="BRCA1">BRCA1</strong>. Cette notation signifie qu‚Äôau niveau du 116·µâ nucl√©otide de la s√©quence codante de l‚ÄôARN messager, la base guanine (G) est remplac√©e par une ad√©nine (A).
                                </p>
                                <p class="lang-mut-brca1-c116-def-p2">
                                    Cette substitution provoque un changement dans le codon correspondant √† l‚Äôacide amin√© <strong class="highlight">Cyst√©ine (Cys)</strong> en un codon codant pour la <strong class="highlight">Tyrosine (Tyr)</strong> √† la position 39 de la prot√©ine BRCA1. Il s'agit donc d'une mutation <strong class="highlight">faux-sens (missense)</strong> not√©e <strong class="highlight">p.Cys39Tyr</strong> (ou p.C39Y).
                                </p>
                            </div>
                            <div class="figure inline-figure" style="flex-basis: 33%; min-width: 1450px; text-align: center;">
                                <a href="https://mutalyzer.nl/normalizer/NM_007294.4:c.116G%3EA" target="_blank" rel="noopener noreferrer">
                                    <img src="Mutation 01 G√®ne BRCA1.jpg" alt="Visualisation Mutalyzer BRCA1 c.116G>A" style="max-height: 220px; object-fit: contain; border:1px solid var(--border-light);" onclick="openInfoModal('Mutation 01 G√®ne BRCA1.jpg', 'Figure: Mutation faux-sens c.116G>A dans BRCA1')">
                                </a>
                                <div class="figure-caption lang-mut-brca1-c116-caption">Figure : Mutation faux-sens c.116G>A (BRCA1). Cliquez pour Mutalyzer.</div>
                            </div>
                        </div>
                        <h5 class="interpretation-subtitle lang-mut-brca1-c116-eff-title">Effets et cons√©quences</h5>
                        <p class="lang-mut-brca1-c116-eff-p1">
                             La cyst√©ine est un acide amin√© petit et faiblement polaire avec un groupe thiol important pour la stabilit√© de la prot√©ine. La tyrosine est plus volumineuse, polaire et aromatique, capable de participer √† la phosphorylation. Le remplacement de la cyst√©ine par la tyrosine peut modifier la structure et la fonction de la prot√©ine BRCA1.
                        </p>
                        <p class="lang-mut-brca1-c116-eff-p2">
                             BRCA1 est une prot√©ine suppresseur de tumeur essentielle √† la r√©paration des cassures double-brin de l‚ÄôADN par recombinaison homologue. La mutation <strong class="highlight">p.Cys39Tyr</strong> peut perturber la structure du <strong class="highlight">domaine RING</strong> √† l'extr√©mit√© N-terminale, qui est crucial pour l'ubiquitination, l'interaction avec BARD1, et le recrutement sur les sites de l√©sion de l'ADN. Une alt√©ration de cette fonction rend la cellule plus vuln√©rable aux mutations, favorisant la canc√©rogen√®se.
                        </p>
                        <h5 class="interpretation-subtitle lang-mut-brca1-protein-viz-title">Visualisation de l'effet prot√©ique</h5>
                        <div class="figure">
                            <a href="https://mutalyzer.nl/normalizer/NM_007294.4(NP_009225.1):p.(Cys39Tyr)" target="_blank" rel="noopener noreferrer">
                                <img src="Mutation Proteine 01.jpg" alt="Visualisation Mutalyzer de l'effet prot√©ique p.Cys39Tyr" style="max-height: 220px; object-fit: contain; border:1px solid var(--border-light);" onclick="openInfoModal('Mutation Proteine 01.jpg', 'Visualisation de l\'effet prot√©ique p.Cys39Tyr (BRCA1)')">
                            </a>
                            <div class="figure-caption lang-mut-brca1-protein-caption">Figure : Visualisation de l'effet prot√©ique p.Cys39Tyr (BRCA1). Cliquez pour Mutalyzer.</div>
                        </div>
                    </div>

                    <div class="mutation-block">
                        <h4 class="interpretation-title-section lang-mut-brca2-c728-title">
                            Variant de l'√âchantillon : G√®ne <span class="gene-info-trigger" data-gene="BRCA2">BRCA2</span> - <span class="highlight">NM_000059.4:c.728del</span>
                        </h4>
                        <h5 class="interpretation-subtitle lang-mut-brca2-c728-def-title">D√©finition et cons√©quences</h5>
                         <div class="horizontal-layout" style="margin-bottom: 1.5rem; align-items: flex-start;">
                             <div class="text-content" style="flex-basis: 65%;">
                                <p class="lang-mut-brca2-c728-def-p1">
                                    La mutation <strong class="highlight">NM_000059.4:c.728del</strong> dans le g√®ne <strong class="gene-info-trigger" data-gene="BRCA2">BRCA2</strong> correspond √† la suppression d‚Äôun nucl√©otide √† la position 728 du transcrit codant.
                                </p>
                                <p class="lang-mut-brca2-c728-def-p2">
                                    Cette d√©l√©tion d‚Äôun seul nucl√©otide provoque un <strong class="highlight">d√©calage du cadre de lecture (frameshift)</strong>, modifiant tous les codons en aval et menant √† l'apparition d'un <strong class="highlight">codon stop pr√©matur√©</strong>. La prot√©ine BRCA2 r√©sultante est tronqu√©e et non fonctionnelle.
                                </p>
                            </div>
                            <div class="figure inline-figure" style="flex-basis: 33%; min-width: 1450px; text-align: center;">
                                <a href="https://mutalyzer.nl/normalizer/NM_000059.4:c.728del" target="_blank" rel="noopener noreferrer">
                                    <img src="Mutation 02 G√®ne BRCA2.jpg" alt="Visualisation Mutalyzer BRCA2 c.728del" style="max-height: 220px; object-fit: contain; border:1px solid var(--border-light);" onclick="openInfoModal('Mutation 02 G√®ne BRCA2.jpg', 'Figure: Mutation d√©calante c.728del dans BRCA2')">
                                </a>
                                <div class="figure-caption lang-mut-brca2-c728-caption">Figure : Mutation d√©calante c.728del (BRCA2). Cliquez pour Mutalyzer.</div>
                            </div>
                        </div>
                        <h5 class="interpretation-subtitle lang-mut-brca2-c728-eff-title">Implications cliniques</h5>
                        <p class="lang-mut-brca2-c728-eff-p1">
                            BRCA2 est un g√®ne suppresseur de tumeur crucial dans la r√©paration de l'ADN par recombinaison homologue. La perte de sa fonction favorise l'accumulation de mutations et le d√©veloppement de cancers.
                        </p>
                        <p class="lang-mut-brca2-c728-eff-p2">
                            Les mutations d√©l√©t√®res comme <strong class="highlight">c.728del</strong> sont associ√©es √† un risque √©lev√© de cancers h√©r√©ditaires (sein, ovaire, prostate, pancr√©as). √âtant une mutation germinale, son d√©pistage est crucial pour la pr√©vention et le suivi m√©dical des familles √† risque.
                        </p>
                         <h5 class="interpretation-subtitle lang-mut-brca2-protein-viz-title">Visualisation de l'effet prot√©ique</h5>
                        <div class="figure">
                            <a href="https://mutalyzer.nl/normalizer/NM_000059.4(NP_000050.3):p.(Ser243IlefsTer5)" target="_blank" rel="noopener noreferrer">
                                <img src="Mutation Proteine 02.jpg" alt="Visualisation Mutalyzer de l'effet prot√©ique p.Ser243IlefsTer5" style="max-height: 220px; object-fit: contain; border:1px solid var(--border-light);" onclick="openInfoModal('Mutation Proteine 02.jpg', 'Visualisation de l\'effet prot√©ique p.Ser243IlefsTer5 (BRCA2)')">
                            </a>
                            <div class="figure-caption lang-mut-brca2-protein-caption">Figure : Visualisation de l'effet prot√©ique p.Ser243IlefsTer5 (BRCA2). Cliquez pour Mutalyzer.</div>
                        </div>
                    </div>

                    <hr style="margin: 3rem 0;">
                    
                    <h3 class="lang-interpretation-freq-mut-header">Exemples Illustratifs de Mutations Fr√©quentes et Leurs Impacts</h3>
                    <div class="table-responsive data-table-container">
                        <table class="data-table">
                            <thead>
                                <tr>
                                    <th class="lang-ex-table-gene">G√®ne</th>
                                    <th class="lang-ex-table-type">Type de Mutation</th>
                                    <th class="lang-ex-table-exon">Exon</th>
                                    <th class="lang-ex-table-nuc">Changement Nucl√©otidique</th>
                                    <th class="lang-ex-table-aa">Changement Acide Amin√©</th>
                                    <th class="lang-ex-table-tumor">Syndrome / Tumeur Associ√©</th>
                                </tr>
                            </thead>
                            <tbody>
                               <tr>
                                    <td><strong class="gene-info-trigger" data-gene="TP53">TP53</strong></td>
                                    <td class="lang-ex-table-tp53-type">Faux-sens (Missense)</td>
                                    <td>Exon 06</td>
                                    <td>c.584T>C</td>
                                    <td>p.Leu195Pro</td>
                                    <td class="lang-ex-table-tp53-syndrome">Syndrome de Li-Fraumeni (sarcomes, seins, cerveau...)</td>
                                </tr>
                                <tr>
                                    <td><strong class="gene-info-trigger" data-gene="MSH2">MSH2</strong></td>
                                    <td class="lang-ex-table-msh2-type">Non-sens (Nonsense)</td>
                                    <td>Exon 13</td>
                                    <td>c.2038C>T</td>
                                    <td>p.Arg680Ter</td>
                                    <td class="lang-ex-table-msh2-syndrome">Syndrome de Lynch (colorectal, endom√®tre...)</td>
                                </tr>
                                <tr>
                                    <td><strong class="gene-info-trigger" data-gene="MSH6">MSH6</strong></td>
                                    <td class="lang-ex-table-msh6-type">Frameshift</td>
                                    <td>Exon 05</td>
                                    <td>c.3261delC</td>
                                    <td>p.Phe1088LeufsTer5</td>
                                    <td class="lang-ex-table-msh6-syndrome">Syndrome de Lynch, Cancer de l'endom√®tre</td>
                                </tr>
                                <tr>
                                    <td><strong class="gene-info-trigger" data-gene="MLH1">MLH1</strong></td>
                                    <td class="lang-ex-table-mlh1-type">Non-sens (Nonsense)</td>
                                    <td> Exon 18</td>
                                    <td>c.2059C>T</td>
                                    <td>p.Arg687Ter</td>
                                    <td class="lang-ex-table-mlh1-syndrome">Syndrome de Lynch (colorectal, endom√®tre...)</td>
                                </tr>
                                <tr>
                                    <td><strong class="gene-info-trigger" data-gene="PTEN">PTEN</strong></td>
                                    <td class="lang-ex-table-pten-type">Faux-sens (Missense)</td>
                                    <td>Exon 05</td>
                                    <td>c.389G>A</td>
                                    <td>p.Arg130Gln</td>
                                    <td class="lang-ex-table-pten-syndrome">Syndrome de Cowden (sein, thyro√Øde, endom√®tre)</td>
                                </tr>
                                <tr>
                                    <td><strong class="gene-info-trigger" data-gene="APC">APC</strong></td>
                                    <td class="lang-ex-table-apc-type">Non-sens (Nonsense)</td>
                                    <td>Exon 15</td>
                                    <td>c.3927_3931delA</td>
                                    <td>p.Glu1309AspfsTer4</td>
                                    <td class="lang-ex-table-apc-syndrome">Polypose ad√©nomateuse familiale (PAF)</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </section>
                       

            <section id="conclusion" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-conclusion-title">Conclusion</h3>
                    <p class="lang-conclusion-p1">
                        Ce mini-projet a permis de mettre en ≈ìuvre un pipeline bioinformatique complet pour l'analyse des donn√©es de s√©quen√ßage du g√©nome entier, en se concentrant sur l'identification des mutations germinales potentiellement impliqu√©es dans les cancers familiaux. En utilisant l'√©chantillon SRR24002947 et en √©tudiant des exemples de mutations connues (<strong class="gene-info-trigger" data-gene="BRCA1">BRCA1</strong>, <strong class="gene-info-trigger" data-gene="MLH1">MLH1</strong>, <strong class="gene-info-trigger" data-gene="TP53">TP53</strong>, <strong class="gene-info-trigger" data-gene="MSH2">MSH2</strong>), nous avons illustr√© les √©tapes cruciales, allant du contr√¥le qualit√© des donn√©es brutes √† l'annotation et √† l'interpr√©tation fonctionnelle et clinique des variants.
                    </p>
                    <p class="lang-conclusion-p2">
                        L'importance d'une d√©marche rigoureuse, incluant l'alignement pr√©cis sur un g√©nome de r√©f√©rence, l'appel de variants sensible et sp√©cifique, et une annotation approfondie √† l'aide de bases de donn√©es comme ClinVar et d'outils comme SnpEff et Mutalyzer, a √©t√© soulign√©e. Nous avons vu comment ces outils permettent de classer les variants en fonction de leur pathog√©nicit√© pr√©sum√©e et de leur impact biologique, ce qui est essentiel pour le conseil g√©n√©tique et la prise en charge clinique des patients et de leurs familles.
                    </p>
                     <p class="lang-conclusion-p3">
                        La cr√©ation d'une base de donn√©es locale pour stocker les r√©sultats d√©montre une approche structur√©e pour la gestion des donn√©es g√©nomiques, bien que pour des applications r√©elles, des syst√®mes plus robustes et s√©curis√©s soient n√©cessaires.
                    </p>
                    <p class="lang-conclusion-p4">
                        Les d√©fis persistent, notamment dans l'interpr√©tation des variants de signification incertaine (VUS), qui requi√®rent des recherches fonctionnelles suppl√©mentaires et une collaboration internationale pour leur classification. N√©anmoins, les avanc√©es en bioinformatique et en g√©nomique continuent de transformer notre compr√©hension des cancers h√©r√©ditaires, ouvrant la voie √† une m√©decine de plus en plus personnalis√©e et pr√©ventive.
                    </p>
                     <p class="lang-conclusion-p5">
                        En d√©finitive, ce projet a non seulement consolid√© nos comp√©tences techniques en bioinformatique, mais a √©galement renforc√© notre appr√©ciation de la complexit√© et de l'impact de la g√©n√©tique dans le domaine de l'oncologie. Les outils et m√©thodes explor√©s ici sont au c≈ìur de la recherche actuelle et future pour lutter contre les cancers familiaux.
                    </p>
                </div>
            </section>
                        <!-- references SECTION -->
             <section id="references" class="tab-content">
                <div class="content-section">
                    <h3 class="lang-ref-title">R√©f√©rences Bibliographiques</h3>
                    <ol class="references-list">
                        <li class="lang-ref-sra-sample">NCBI Sequence Read Archive. Submission SRR24002947 (BioProject PRJNA949945). Acc√©d√© le [Date d'acc√®s]. Disponible sur : <a href="https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947" target="_blank">https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947</a></li>
                        <li class="lang-ref-grobner">Gr√∂bner, S. N., Worst, B. C., Weischenfeldt, J., et al. (2018). The landscape of genomic alterations across childhood cancers. <em>Nature</em>, 555(7696), 321‚Äì327. <a href="https://doi.org/10.1038/nature25480" target="_blank">https://doi.org/10.1038/nature25480</a></li>
                        <li class="lang-ref-nccn">NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines¬Æ). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2024 (ou la version que vous avez consult√©e). National Comprehensive Cancer Network. Acc√©d√© le [Date d'acc√®s]. Disponible sur : [Lien si possible, sinon mentionner NCCN.org]</li>
                        <li class="lang-ref-petrucelli">Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010, r√©vis√© 2023). BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In Adam, M. P., et al. (Eds.), <em>GeneReviews¬Æ</em>. University of Washington, Seattle. Acc√©d√© le [Date d'acc√®s]. Disponible sur : <a href="https://www.ncbi.nlm.nih.gov/books/NBK1247/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK1247/</a></li>
                        <li class="lang-ref-acmg">Richards, S., Aziz, N., Bale, S., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. <em>Genetics in Medicine</em>, 17(5), 405‚Äì424. <a href="https://doi.org/10.1038/gim.2015.30" target="_blank">https://doi.org/10.1038/gim.2015.30</a></li>
                        <li class="lang-ref-fastqc">Andrews, S. (2010). FastQC: A Quality Control tool for High Throughput Sequence Data. Disponible sur : <a href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/" target="_blank">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</a></li>
                        <li class="lang-ref-trimmomatic">Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. <em>Bioinformatics</em>, 30(15), 2114‚Äì2120. <a href="https://doi.org/10.1093/bioinformatics/btu170" target="_blank">https://doi.org/10.1093/bioinformatics/btu170</a></li>
                        <li class="lang-ref-bowtie2">Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. <em>Nature Methods</em>, 9(4), 357‚Äì359. <a href="https://doi.org/10.1038/nmeth.1923" target="_blank">https://doi.org/10.1038/nmeth.1923</a></li>
                        <li class="lang-ref-samtools">Li, H., Handsaker, B., Wysoker, A., et al. (2009). The Sequence Alignment/Map format and SAMtools. <em>Bioinformatics</em>, 25(16), 2078‚Äì2079. <a href="https://doi.org/10.1093/bioinformatics/btp352" target="_blank">https://doi.org/10.1093/bioinformatics/btp352</a> (Pour Samtools) et Danecek, P., Bonfield, J.K., Liddle, J. et al. (2021) Twelve years of SAMtools and BCFtools. <em>GigaScience</em>, 10(2), giab008. <a href="https://doi.org/10.1093/gigascience/giab008" target="_blank">https://doi.org/10.1093/gigascience/giab008</a> (Pour Bcftools)</li>
                        <li class="lang-ref-freebayes">Garrison, E., & Marth, G. (2012). Haplotype-based variant detection from short-read sequencing. arXiv:1207.3907 [q-bio.GN]. Disponible sur : <a href="https://arxiv.org/abs/1207.3907" target="_blank">https://arxiv.org/abs/1207.3907</a></li>
                        <li class="lang-ref-snpeff">Cingolani, P., Platts, A., Wang, L. L., et al. (2012). A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. <em>Fly</em>, 6(2), 80‚Äì92. <a href="https://doi.org/10.4161/fly.19695" target="_blank">https://doi.org/10.4161/fly.19695</a></li>
                        <li class="lang-ref-vep">McLaren, W., Gil, L., Hunt, S. E., et al. (2016). The Ensembl Variant Effect Predictor. <em>Genome Biology</em>, 17(1), 122. <a href="https://doi.org/10.1186/s13059-016-0974-4" target="_blank">https://doi.org/10.1186/s13059-016-0974-4</a></li>
                        <li class="lang-ref-mutalyzer">Wildeman, M., van Ophuizen, E., den Dunnen, J. T., & Taschner, P. E. (2008). Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. <em>Human Mutation</em>, 29(1), 6‚Äì13. <a href="https://doi.org/10.1002/humu.20611" target="_blank">https://doi.org/10.1002/humu.20611</a></li>
                        <li class="lang-ref-clinvar">Landrum, M. J., Lee, J. M., Benson, M., et al. (2018). ClinVar: improving access to variant interpretations and supporting evidence. <em>Nucleic Acids Research</em>, 46(D1), D1062‚ÄìD1067. <a href="https://doi.org/10.1093/nar/gkx1153" target="_blank">https://doi.org/10.1093/nar/gkx1153</a></li>
                        <li class="lang-ref-galaxy">Afgan, E., Baker, D., Batut, B., et al. (2018). The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. <em>Nucleic Acids Research</em>, 46(W1), W537‚ÄìW544. <a href="https://doi.org/10.1093/nar/gky379" target="_blank">https://doi.org/10.1093/nar/gky379</a> (Pour la plateforme Galaxy en g√©n√©ral)</li>
                    </ol>
                    <div class="contact-section">
                        <h4 class="lang-contact">Contactez-nous</h4>
                        <div class="contact-grid">
                            <div class="contact-card"><div class="contact-name">Mezghiche Ichrak</div><a href="mailto:ichrak.mezghiche@student.umc.edu.dz" class="contact-email">ichrak.mezghiche@student.umc.edu.dz</a></div>
                            <div class="contact-card"><div class="contact-name">Attar Ouail Abd ElDjalil</div><a href="mailto:ouailabdeldjalil.attar@student.umc.edu.dz" class="contact-email">ouailabdeldjalil.attar@student.umc.edu.dz</a></div>
                            <div class="contact-card"><div class="contact-name">Boughachiche Belkis</div><a href="mailto:Boughachiche.Belkis@student.umc.edu.dz" class="contact-email">Boughachiche.Belkis@student.umc.edu.dz</a></div>
                            <div class="contact-card"><div class="contact-name">Derder Malak</div><a href="mailto:Derder.Malak@student.umc.edu.dz" class="contact-email">Derder.Malak@student.umc.edu.dz</a></div>
                        </div>
                    </div>
                </div>
            </section>

        </div>
    </div>

    <!-- Modal Structure (pour images et infos g√®nes) -->
    <div id="infoModal" class="info-modal">
        <div class="info-modal-content">
            <span class="info-modal-close" onclick="closeInfoModal()">√ó</span>
            <h3 id="infoModalTitle"></h3>
            <img id="infoModalImage" src="" alt="Image agrandie">
            <p id="infoModalFigcaption"></p>
            <div id="infoModalBody"></div>
        </div>
    </div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.6.0/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/lightbox2/2.11.3/js/lightbox.min.js"></script>
<script>
    // --- Gene Info Data ---
    const geneData = {
        "BRCA1": {
            title: "Information sur le g√®ne BRCA1", title_en: "Information about BRCA1 Gene",
            symbol: "BRCA1", fullName: "BRCA1 DNA repair associated", fullName_en: "BRCA1 DNA repair associated", idGene: "672",
            definition: "Ce g√®ne code une phosphoprot√©ine nucl√©aire de 190 kDa impliqu√©e dans le maintien de la stabilit√© g√©nomique, et exerce √©galement une fonction de suppresseur de tumeurs. Le g√®ne BRCA1 est constitu√© de 22 exons r√©partis sur environ 110 kb d‚ÄôADN. La prot√©ine cod√©e s'associe √† d'autres suppresseurs de tumeurs, capteurs de dommages √† l'ADN et transducteurs de signal pour former un complexe multiprot√©ique de grande taille, connu sous le nom de BASC (BRCA1-associated genome surveillance complex).<br>Le produit de ce g√®ne interagit avec l'ARN polym√©rase II et, via son domaine C-terminal, se lie √©galement aux complexes d'histone d√©sac√©tylase. Cette prot√©ine joue ainsi un r√¥le cl√© dans la transcription, la r√©paration de l'ADN, notamment des cassures double-brin, ainsi que dans la recombinaison homologue.<br>Les mutations du g√®ne BRCA1 sont responsables d‚Äôenviron 40 % des cancers du sein h√©r√©ditaires et de plus de 80 % des cas de cancers h√©r√©ditaires du sein et de l‚Äôovaire. Le trans-√©pissage alternatif contribue √† moduler la localisation subcellulaire et la fonction physiologique de cette prot√©ine. De nombreux transcrits variants issus d‚Äôun √©pissage alternatif ont √©t√© d√©crits pour ce g√®ne, certains √©tant associ√©s √† des mutations pathog√®nes. Cependant, la structure compl√®te n‚Äôa √©t√© caract√©ris√©e que pour une partie de ces variants.<br>Un pseudo-g√®ne homologue, √©galement localis√© sur le chromosome 17, a √©galement √©t√© identifi√©.",
            definition_en: "This gene encodes a 190 kDa nuclear phosphoprotein involved in maintaining genomic stability and also functions as a tumor suppressor. The BRCA1 gene consists of 22 exons spanning approximately 110 kb of DNA. The encoded protein associates with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multiprotein complex known as BASC (BRCA1-associated genome surveillance complex).<br>The product of this gene interacts with RNA polymerase II and, via its C-terminal domain, also binds to histone deacetylase complexes. This protein thus plays a key role in transcription, DNA repair (particularly double-strand breaks), and homologous recombination.<br>Mutations in the BRCA1 gene are responsible for approximately 40% of hereditary breast cancers and over 80% of hereditary breast and ovarian cancers. Alternative trans-splicing helps modulate the subcellular localization and physiological function of this protein. Numerous alternatively spliced transcript variants have been described for this gene, some associated with pathogenic mutations. However, the full-length nature has only been characterized for a subset of these variants.<br>A homologous pseudogene, also located on chromosome 17, has also been identified."
        },
        "BRCA2": {
            title: "Information sur le g√®ne BRCA2", title_en: "Information about BRCA2 Gene",
            symbol: "BRCA2", fullName: "BRCA2 DNA repair associated", fullName_en: "BRCA2 DNA repair associated", idGene: "675",
            definition: "Les mutations h√©r√©ditaires dans BRCA1 et dans ce g√®ne, BRCA2, entra√Ænent une augmentation significative du risque √† vie de d√©velopper un cancer du sein ou de l‚Äôovaire. Les deux g√®nes jouent un r√¥le essentiel dans le maintien de la stabilit√© g√©nomique, en particulier dans la voie de la recombinaison homologue, un m√©canisme cl√© de r√©paration des cassures double-brin de l‚ÄôADN.<br>Chez les deux g√®nes, l‚Äôexon 11 est le plus grand et constitue le site principal des mutations pathog√®nes observ√©es chez les patientes atteintes de cancer du sein.<br>Le g√®ne BRCA2 est localis√© sur le chromosome 13q12.3 chez l‚Äôhumain. La prot√©ine BRCA2 contient plusieurs copies d‚Äôun motif de 70 acides amin√©s appel√© motif BRC, qui permet l‚Äôinteraction avec la recombinase RAD51, une enzyme cl√© dans la r√©paration de l‚ÄôADN par recombinaison homologue.<br>BRCA2 est consid√©r√© comme un g√®ne suppresseur de tumeurs, car les tumeurs pr√©sentant des mutations dans BRCA2 montrent g√©n√©ralement une perte d‚Äôh√©t√©rozygotie (LOH) de l‚Äôall√®le sauvage.",
            definition_en: "Hereditary mutations in BRCA1 and this gene, BRCA2, lead to a significant lifetime increased risk of developing breast or ovarian cancer. Both genes play an essential role in maintaining genomic stability, particularly in the homologous recombination pathway, a key mechanism for repairing DNA double-strand breaks.<br>In both genes, exon 11 is the largest and is the primary site of pathogenic mutations observed in breast cancer patients.<br>The BRCA2 gene is located on chromosome 13q12.3 in humans. The BRCA2 protein contains multiple copies of a 70-amino acid motif called the BRC motif, which allows interaction with the recombinase RAD51, a key enzyme in DNA repair by homologous recombination.<br>BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally show loss of heterozygosity (LOH) of the wild-type allele."
        },
        "MSH2": {
            title: "Information sur le g√®ne MSH2", title_en: "Information about MSH2 Gene",
            symbol: "MSH2", fullName: "mutS homolog 2", fullName_en: "mutS homolog 2", idGene: "4436",
            definition: "Ce locus est fr√©quemment mut√© dans le cancer colorectal h√©r√©ditaire non polyposique (HNPCC). Lors de son clonage, il a √©t√© identifi√© comme un homologue humain du g√®ne de r√©paration des m√©sappariements de l'ADN mutS chez E. coli, ce qui est coh√©rent avec les alt√©rations caract√©ristiques des s√©quences microsatellites (ph√©notype RER+) observ√©es dans le HNPCC. Deux variants de transcription codant pour des isoformes diff√©rentes ont √©t√© identifi√©s pour ce g√®ne.",
            definition_en: "This locus is frequently mutated in hereditary nonpolyposis colorectal cancer (HNPCC). When cloned, it was discovered to be a human homolog of the E. coli mismatch repair gene mutS, consistent with the characteristic alterations in microsatellite sequences (RER+ phenotype) found in HNPCC. Two transcript variants encoding different isoforms have been identified for this gene."
        },
        "MSH6": {
            title: "Information sur le g√®ne MSH6", title_en: "Information about MSH6 Gene",
            symbol: "MSH6", fullName: "mutS homolog 6", fullName_en: "mutS homolog 6", idGene: "2956",
            definition: "Ce g√®ne code une prot√©ine appartenant √† la famille MutS impliqu√©e dans la r√©paration des m√©sappariements de l‚ÄôADN. Chez E. coli, la prot√©ine MutS intervient dans la reconnaissance des nucl√©otides mal appari√©s avant leur r√©paration. Une r√©gion hautement conserv√©e d‚Äôenviron 150 acides amin√©s, appel√©e motif de liaison √† l‚Äôad√©nine nucl√©otidique Walker-A, est pr√©sente dans les homologues de MutS. La prot√©ine cod√©e forme un h√©t√©rodim√®re avec MSH2 pour constituer un complexe de reconnaissance des m√©sappariements fonctionnant comme un interrupteur mol√©culaire bidirectionnel, √©changeant l‚ÄôADP et l‚ÄôATP lors de la liaison et de la dissociation des m√©sappariements de l‚ÄôADN. Des mutations de ce g√®ne peuvent √™tre associ√©es au cancer colorectal h√©r√©ditaire non polyposique, au cancer colorectal sporadique ainsi qu‚Äôau cancer de l‚Äôendom√®tre. Des variants de transcription codant pour diff√©rentes isoformes ont √©t√© d√©crits.",
            definition_en: "This gene encodes a protein belonging to the MutS family involved in DNA mismatch repair. In E. coli, the MutS protein is involved in the recognition of mismatched nucleotides before their repair. A highly conserved region of about 150 amino acids, called the Walker-A adenine nucleotide binding motif, is present in MutS homologs. The encoded protein heterodimerizes with MSH2 to form a mismatch recognition complex that functions as a bidirectional molecular switch, exchanging ADP and ATP upon binding to and dissociation from DNA mismatches. Mutations in this gene can be associated with hereditary non-polyposis colorectal cancer, sporadic colorectal cancer, as well as endometrial cancer. Transcript variants encoding different isoforms have been described."
        },
        "MLH1": {
            title: "Information sur le g√®ne MLH1", title_en: "Information about MLH1 Gene",
            symbol: "MLH1", fullName: "mutL homolog 1", fullName_en: "mutL homolog 1", idGene: "4292",
            definition: "La prot√©ine cod√©e par ce g√®ne peut former un h√©t√©rodim√®re avec l‚Äôendonucl√©ase de r√©paration des m√©sappariements PMS2 pour constituer le complexe MutL alpha, qui fait partie du syst√®me de r√©paration des m√©sappariements de l‚ÄôADN. Lorsque MutL alpha est recrut√© par le complexe MutS b√™ta en pr√©sence de certaines prot√©ines accessoires, la sous-unit√© PMS2 introduit une coupure simple brin √† proximit√© du m√©sappariement, cr√©ant un point d‚Äôentr√©e pour la d√©gradation par des exonucl√©ases. La prot√©ine cod√©e joue √©galement un r√¥le dans la signalisation des dommages √† l‚ÄôADN et peut s‚Äôh√©t√©rodim√©riser avec la prot√©ine de r√©paration des m√©sappariements MLH3 pour former le complexe MutL gamma, impliqu√© dans la m√©iose. Ce g√®ne a √©t√© identifi√© comme un locus fr√©quemment mut√© dans le cancer colorectal h√©r√©ditaire non polyposique (HNPCC).",
            definition_en: "The protein encoded by this gene can form a heterodimer with the mismatch repair endonuclease PMS2 to form the MutL alpha complex, which is part of the DNA mismatch repair system. When MutL alpha is recruited by the MutS beta complex in the presence of certain accessory proteins, the PMS2 subunit introduces a single-strand break near the mismatch, creating an entry point for degradation by exonucleases. The encoded protein also plays a role in DNA damage signaling and can heterodimerize with the mismatch repair protein MLH3 to form the MutL gamma complex, which is involved in meiosis. This gene has been identified as a frequently mutated locus in hereditary non-polyposis colorectal cancer (HNPCC)."
        },
        "PTEN": {
            title: "Information sur le g√®ne PTEN", title_en: "Information about PTEN Gene",
            symbol: "PTEN", fullName: "phosphatase and tensin homolog", fullName_en: "phosphatase and tensin homolog", idGene: "5728",
            definition: "Ce g√®ne a √©t√© identifi√© comme un suppresseur de tumeur fr√©quemment mut√© dans un grand nombre de cancers. La prot√©ine cod√©e par ce g√®ne est une phosphatase du phosphatidylinositol-3,4,5-trisphosphate (PIP3 3-phosphatase). Elle contient un domaine de type tensine ainsi qu‚Äôun domaine catalytique similaire √† celui des phosphatases √† double sp√©cificit√© des tyrosines. Contrairement √† la majorit√© des phosphatases des prot√©ines tyrosines, cette prot√©ine d√©phosphoryle pr√©f√©rentiellement les substrats de type phosphoinositide. Elle r√©gule n√©gativement les niveaux intracellulaires de PIP3 et agit comme un suppresseur tumoral en inhibant la voie de signalisation AKT/PKB. L'utilisation d'un site d‚Äôinitiation non canonique en amont (CUG) produit une isoforme plus longue, dont la traduction d√©bute par une leucine ; cette forme est suppos√©e √™tre pr√©f√©rentiellement associ√©e √† la membrane interne des mitochondries. Cette isoforme pourrait jouer un r√¥le dans la r√©gulation du m√©tabolisme √©nerg√©tique mitochondrial. Un pseudog√®ne de ce g√®ne est localis√© sur le chromosome 9. L‚Äô√©pissage alternatif et l‚Äôutilisation de plusieurs codons d‚Äôinitiation de la traduction donnent lieu √† plusieurs variants de transcription codant pour diff√©rentes isoformes.",
            definition_en: "This gene was identified as a tumor suppressor that is mutated in a large number of cancers. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin-like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. Use of a non-canonical (CUG) upstream initiation site produces a longer isoform that is thought to be preferentially associated with the mitochondrial inner membrane. This isoform may be involved in the regulation of mitochondrial energetic metabolism. A pseudogene of this gene is found on chromosome 9. Alternative splicing and the use of multiple translation start codons result in multiple transcript variants encoding different isoforms."
        },
        "TP53": {
            title: "Information sur le g√®ne TP53", title_en: "Information about TP53 Gene",
            symbol: "TP53", fullName: "tumor protein p53", fullName_en: "tumor protein p53", idGene: "7157",
            definition: "Ce g√®ne code une prot√©ine suppresseur de tumeur poss√©dant des domaines d‚Äôactivation transcriptionnelle, de liaison √† l‚ÄôADN et d‚Äôoligom√©risation. La prot√©ine cod√©e r√©agit √† divers stress cellulaires afin de r√©guler l‚Äôexpression de g√®nes cibles, induisant ainsi l‚Äôarr√™t du cycle cellulaire, l‚Äôapoptose, la s√©nescence, la r√©paration de l‚ÄôADN ou des modifications du m√©tabolisme. Des mutations de ce g√®ne sont associ√©es √† divers cancers humains, y compris des cancers h√©r√©ditaires tels que le syndrome de Li-Fraumeni. L‚Äô√©pissage alternatif de ce g√®ne ainsi que l‚Äôutilisation de promoteurs alternatifs conduisent √† la production de plusieurs variants de transcription et isoformes. Des isoformes suppl√©mentaires r√©sultent √©galement de l‚Äôutilisation de codons d‚Äôinitiation de la traduction alternatifs √† partir de variants de transcription identiques (PMIDs : 12032546, 20937277).",
            definition_en: "This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons from identical transcript variants (PMIDs: 12032546, 20937277)."
        },
        "APC": {
            title: "Information sur le g√®ne APC", title_en: "Information about APC Gene",
            symbol: "APC", fullName: "APC regulator of WNT signaling pathway", fullName_en: "APC regulator of WNT signaling pathway", idGene: "324",
            definition: "Ce g√®ne code une prot√©ine suppresseur de tumeur qui agit comme un antagoniste de la voie de signalisation Wnt. Il est √©galement impliqu√© dans d'autres processus, notamment la migration et l‚Äôadh√©sion cellulaires, l‚Äôactivation transcriptionnelle et l‚Äôapoptose. Des anomalies de ce g√®ne sont √† l‚Äôorigine de la polypose ad√©nomateuse familiale (PAF), une maladie pr√©-maligne autosomique dominante qui √©volue g√©n√©ralement vers une tumeur maligne. Des mutations du g√®ne APC ont √©t√© identifi√©es dans la majorit√© des cancers colorectaux ; les mutations pathog√®nes sont souvent regroup√©es dans une r√©gion restreinte appel√©e mutation cluster region (MCR), conduisant √† la production d‚Äôune prot√©ine tronqu√©e.",
            definition_en: "This gene encodes a tumor suppressor protein that acts as an antagonist of the Wnt signaling pathway. It is also involved in other processes including cell migration and adhesion, transcriptional activation, and apoptosis. Defects in this gene cause familial adenomatous polyposis (FAP), an autosomal dominant pre-malignant disease that usually progresses to malignancy. Disease-associated mutations tend to be clustered in a small region designated the mutation cluster region (MCR) and result in a truncated protein product."
        }
    };

    const infoModal = document.getElementById('infoModal');
    const modalTitle = document.getElementById('infoModalTitle');
    const modalImage = document.getElementById('infoModalImage');
    const modalFigcaption = document.getElementById('infoModalFigcaption');
    const modalBody = document.getElementById('infoModalBody');
    
    // --- Translation Data ---
    const translations = {
        'fr': {
            'login-title': "Acc√®s au Mini Projet", 'login-btn': "Se connecter",
            'home': "Accueil", 'intro-menu': "Introduction",
            'matmeth-projet-menu': "Mat√©riel & D√©finition", 'pipeline-projet-menu': "Pipeline Projet",
            'conclusion-menu': "Conclusion", 'ref-menu': "R√©f√©rences",
            'republique': "R√©publique Alg√©rienne D√©mocratique et Populaire",
            'ministere': "Minist√®re de l'Enseignement Sup√©rieur et de la Recherche Scientifique",
            'universite': "Universit√© Fr√®res Mentouri Constantine 1",
            'faculte': "Facult√© des Sciences de la Nature et de la Vie",
            'departement': "D√©partement de Biologie Appliqu√©e",
            'title': "Analyse Transcriptomique du Cancer du Poumon: Pipeline RNA‚Äëseq complet. (Analyse comparative du transcriptome entre tissus tumoraux et tissus pulmonaires sains).",
            'presented': "Pr√©sent√© par :", 'promo': "Promo 2026",
            'plan': "Plan de Travail",
            'plan-generality': "Introduction", 'plan-intro': "‚Æï Introduction", 'plan-def-cf': "‚Æï D√©finition des Cancers Familiaux",
            'plan-types-cf': "‚Æï Types de Cancers Familiaux", 'plan-facteurs-cf': "‚Æï Facteurs de Risque des Cancers Familiaux",
            'plan-symptomes-cf': "‚Æï Sympt√¥mes Cliniques des Cancers Familiaux", 'plan-stades-cf': "‚Æï Stades des Cancers Familiaux",
            'plan-matmeth': "Mat√©riel et M√©thodes du Projet", 'plan-pipeline': "Description du Pipeline du Projet",
            'plan-resultats': "R√©sultats du Projet", 'plan-interpretation': "Interpr√©tation des R√©sultats et Conclusion",
            'plan-database': "Base de Donn√©es du Projet", 'plan-conclusion': "Conclusion", 'plan-ref': "R√©f√©rences Bibliographiques",
            'intro-generale-title': "Introduction",
            'intro-generale-p1': "Les cancers familiaux repr√©sentent un ensemble de pathologies canc√©reuses qui apparaissent avec une fr√©quence accrue dans certaines familles en raison de mutations g√©n√©tiques h√©r√©ditaires. Ces mutations, transmises de mani√®re mend√©lienne d'une g√©n√©ration √† l'autre, augmentent significativement le risque de d√©velopper des tumeurs sp√©cifiques.",
            'intro-generale-p2': "La compr√©hension des mutations germinales, qui affectent les cellules reproductrices et sont donc pr√©sentes dans toutes les cellules de l'organisme, est essentielle pour la d√©tection pr√©coce, la pr√©vention cibl√©e et le traitement personnalis√© de ces cancers familiaux. Ce projet vise √† mettre en ≈ìuvre un pipeline bioinformatique pour analyser des donn√©es de s√©quen√ßage (l'√©chantillon SRR24002947) afin d'identifier de telles mutations.",
            'mutation-table-type': "Type de Mutation", 'mutation-table-char': "Caract√©ristiques",
            'mutation-table-germ': "Mutation Germinale", 'mutation-table-germ-desc': "Pr√©sente dans les gam√®tes (ovules et spermatozo√Ødes) ‚Üí Transmise √† la descendance ‚Üí Pr√©sente dans toutes les cellules de l'organisme. Peut augmenter le risque de cancer.",
            'mutation-table-som': "Mutation Somatique", 'mutation-table-som-desc': "Acquise au cours de la vie dans une cellule non germinale ‚Üí Non h√©r√©ditaire ‚Üí Affecte uniquement un sous-ensemble de cellules (ex: tumeur). Principale cause des cancers sporadiques.",
            'def-cf-title': "D√©finition des Cancers Familiaux",
            'def-cf-p1': "Les cancers familiaux (ou h√©r√©ditaires) sont des n√©oplasies dont la pr√©disposition g√©n√©tique est h√©rit√©e selon des modalit√©s mend√©liennes. Contrairement aux cancers sporadiques, qui surviennent de mani√®re al√©atoire sous l'influence de facteurs environnementaux et de mutations somatiques acquises, les cancers familiaux sont principalement li√©s √† des mutations constitutionnelles (germinales) transmises verticalement d'une g√©n√©ration √† l'autre.",
            'def-cf-p2': "Ces mutations pathog√®nes affectent g√©n√©ralement des g√®nes cl√©s impliqu√©s dans :",
            'def-cf-li1': "La r√©paration des l√©sions de l'ADN (ex: <strong class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</strong>, <strong class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</strong>, g√®nes du syst√®me MMR)",
            'def-cf-li2': "La r√©gulation du cycle cellulaire (ex: <strong class=\"gene-info-trigger\" data-gene=\"TP53\">TP53</strong>, RB1)",
            'def-cf-li3': "Les voies de signalisation intracellulaire (ex: <strong class=\"gene-info-trigger\" data-gene=\"APC\">APC</strong>, <strong class=\"gene-info-trigger\" data-gene=\"PTEN\">PTEN</strong>)",
            'def-cf-li4': "L'apoptose (mort cellulaire programm√©e)",
            'def-cf-p3': "La pr√©sence d'une telle mutation ne signifie pas que l'individu d√©veloppera syst√©matiquement un cancer, mais son risque est consid√©rablement accru par rapport √† la population g√©n√©rale.",
            'fig1cf': "Figure 01: M√©canismes mol√©culaires impliqu√©s dans les cancers familiaux.",
            'types-cf-title': "Principaux Types de Syndromes de Cancers Familiaux",
            'types-cf-h4-1': "1. Syndrome Seins-Ovaires H√©r√©ditaire",
            'types-cf-p1': "Principalement d√ª √† des mutations des g√®nes <strong class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</strong> et <strong class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</strong>, impliqu√©s dans la r√©paration de l'ADN. Augmente consid√©rablement le risque de :",
            'types-cf-li1': "40-85% de risque de cancer du sein (vs 12% en population g√©n√©rale)",
            'types-cf-li2': "10-40% de risque de cancer de l'ovaire (vs 1-2%)",
            'types-cf-li3': "Repr√©sentent 5-10% des cancers du sein et 15% des cancers ovariens",
            'types-cf-h4-2': "2. Cancer Colorectal H√©r√©ditaire",
            'types-cf-p2': "Principalement associ√© √† :",
            'types-cf-lynch': "Syndrome de Lynch (g√®nes <strong class=\"gene-info-trigger\" data-gene=\"MLH1\">MLH1</strong>, <strong class=\"gene-info-trigger\" data-gene=\"MSH2\">MSH2</strong>, <strong class=\"gene-info-trigger\" data-gene=\"MSH6\">MSH6</strong>, PMS2)",
            'types-cf-paf': "Polypose ad√©nomateuse familiale (g√®ne <strong class=\"gene-info-trigger\" data-gene=\"APC\">APC</strong>)",
            'types-cf-li4': "Risque cumulatif √† 70 ans : 50-80% (vs 5% en population g√©n√©rale)",
            'types-cf-h4-prostate': "3. Cancer de la Prostate Familial",
            'types-cf-p3': "Associ√© notamment aux mutations :",
            'types-cf-li5': "<strong class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</strong> (risque augment√© de 5 √† 8 fois)",
            'types-cf-li6': "HOXB13",
            'types-cf-li7': "ATM, CHEK2",
            'types-cf-h4-lynchdetail': "4. Syndrome de Lynch (d√©tail)",
            'types-cf-p4': "Augmente le risque de :",
            'types-cf-li8': "Cancer de l'endom√®tre (40-60% de risque)",
            'types-cf-li9': "Cancer de l'ovaire (10-12%)",
            'types-cf-li10': "Autres cancers (estomac, intestin gr√™le, voies urinaires)",
            'factors-cf-title': "Facteurs de Risque des Cancers Familiaux",
            'factors-cf-li1': "<strong>Ant√©c√©dents familiaux :</strong> Occurrence de cancers similaires chez plusieurs apparent√©s au 1<sup>er</sup> degr√© (parents, fratrie, enfants)",
            'factors-cf-li2': "<strong>Mutations constitutionnelles :</strong> Alt√©rations pathog√®nes dans des g√®nes de pr√©disposition (<strong class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</strong>/<strong class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</strong>, <strong class=\"gene-info-trigger\" data-gene=\"APC\">APC</strong>, <strong class=\"gene-info-trigger\" data-gene=\"MLH1\">MLH1</strong>/<strong class=\"gene-info-trigger\" data-gene=\"MSH2\">MSH2</strong>, etc.)",
            'factors-cf-li3': "<strong>√Çge de survenue pr√©coce :</strong> Apparition des tumeurs √† un √¢ge significativement plus jeune que la moyenne",
            'factors-cf-li4': "<strong>Ph√©notype particulier :</strong> Multiplicit√© des tumeurs, localisations sp√©cifiques, associations syndromiques",
            'factors-cf-li5': "<strong>Facteurs √©pig√©n√©tiques :</strong> Modifications de l'expression g√©nique sans alt√©ration de la s√©quence d'ADN",
            'factors-cf-li6': "<strong>Interactions g√®ne-environnement :</strong> Potentialisation des risques par des facteurs externes (tabac, alcool, rayonnements)",
            'symptoms-cf-title': "Manifestations Cliniques",
            'symptoms-cf-h4-sein': "Cancer du Sein",
            'symptoms-cf-sein1': "Nodule palpable indolore", 'symptoms-cf-sein2': "Modifications cutan√©es (peau d'orange, r√©traction)",
            'symptoms-cf-sein3': "√âcoulement mamelonnaire", 'symptoms-cf-sein4': "Ad√©nopathies axillaires",
            'symptoms-cf-h4-colo': "Cancer Colorectal",
            'symptoms-cf-colo1': "Rectorragies (saignements rectaux)", 'symptoms-cf-colo2': "Alt√©ration du transit intestinal (diarrh√©e/constipation)",
            'symptoms-cf-colo3': "Douleurs abdominales persistantes", 'symptoms-cf-colo4': "An√©mie ferriprive inexpliqu√©e",
            'symptoms-cf-h4-pros': "Cancer de la Prostate",
            'symptoms-cf-pros1': "Dysurie (difficult√© √† uriner)", 'symptoms-cf-pros2': "Pollakiurie (mictions fr√©quentes)",
            'symptoms-cf-pros3': "H√©maturie (sang dans les urines)", 'symptoms-cf-pros4': "Douleurs pelviennes ou lombaires",
            'symptoms-cf-h4-ova': "Cancer de l'Ovaire",
            'symptoms-cf-ova1': "M√©t√©orisme abdominal (ballonnements)", 'symptoms-cf-ova2': "Douleurs pelviennes chroniques",
            'symptoms-cf-ova3': "Troubles digestifs non sp√©cifiques", 'symptoms-cf-ova4': "Augmentation du volume abdominal",
            'stages-cf-title': "Stadification des Cancers",
            'stages-cf-p1': "La classification TNM (Tumeur, Node, Metastasis) est utilis√©e pour √©valuer l'extension des cancers familiaux, comme pour les formes sporadiques :",
            'stages-table-stade': "Stade", 'stages-table-carac': "Caract√©ristiques", 'stages-table-prog': "Pronostic",
            'stages-cf-s1': "Stade I", 'stages-cf-s1d': "Tumeur localis√©e, limit√©e au tissu d'origine", 'stages-cf-s1p': "Excellent (survie >90% √† 5 ans)",
            'stages-cf-s2': "Stade II", 'stages-cf-s2d': "Extension locale aux tissus adjacents", 'stages-cf-s2p': "Bon (survie 70-90%)",
            'stages-cf-s3': "Stade III", 'stages-cf-s3d': "Atteinte des ganglions lymphatiques r√©gionaux", 'stages-cf-s3p': "Interm√©diaire (survie 30-70%)",
            'stages-cf-s4': "Stade IV", 'stages-cf-s4d': "M√©tastases √† distance (foie, poumon, os, etc.)", 'stages-cf-s4p': "R√©serv√© (survie <30%)",
            'matmeth-projet-title': "Mat√©riel et M√©thodes",
            'matmeth-data-and-setup': "Donn√©es, G√©nome de R√©f√©rence et Plateforme d'Analyse Principale",
            'matmeth-projet-data': "Donn√©es Utilis√©es :",
            'matmeth-projet-sample': "√âchantillon : <a href=\"https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947\" target=\"_blank\" rel=\"noopener noreferrer\">SRR24002947</a> (accessible sur NCBI SRA).",
            'matmeth-projet-type': "Type de donn√©es : S√©quen√ßage du G√©nome Entier (Whole Genome Sequencing - WGS).",
            'matmeth-projet-origin': "Origine : √âchantillon de sang d'un patient p√©diatrique (√©tude Gr√∂bner et al., Nature 2018).",
            'matmeth-projet-refgenome': "G√©nome de R√©f√©rence :", 'matmeth-projet-refgenomeval': "GRCh38/hg38",
            'matmeth-projet-mainplatform': "Plateforme d'Analyse Principale :",
            'matmeth-software-resources': "Logiciels et Ressources en Ligne Utilis√©s",
            'matmeth-software-intro': "Pour mener √† bien ce projet, divers logiciels, plateformes d'analyse et bases de donn√©es ont √©t√© employ√©s :",
            'matmeth-configpc': "Configurations des Postes de Travail Utilis√©s :",
            'configpc-poste': "Poste", 'configpc-carac': "Caract√©ristique", 'configpc-val': "Valeur",
            'configpc-devname': "Nom de l'appareil", 'configpc-proc': "Processeur", 'configpc-ram': "M√©moire RAM install√©e",
            'configpc-systype': "Type du syst√®me", 'configpc-winedition': "√âdition Windows", 'configpc-winver': "Version Windows",
            'configpc-installdate': "Install√© le", 'configpc-build': "Build du syst√®me d‚Äôexploitation",
            'pipeline-whatis': "Un pipeline Bioinformatique",
            'pipeline-whatis-desc': "Un pipeline bioinformatique est une suite structur√©e d‚Äô√©tapes ou d‚Äôoutils utilis√©s pour traiter, analyser et interpr√©ter des donn√©es biologiques, souvent de mani√®re automatis√©e. Dans le cas des donn√©es de s√©quen√ßage, un pipeline permet de passer d‚Äôun fichier brut (comme un fichier FASTQ) jusqu‚Äô√† l‚Äôidentification et l‚Äôannotation de variants g√©n√©tiques, √† travers des √©tapes comme le contr√¥le qualit√©, le nettoyage, l‚Äôalignement, et l‚Äôappel de variants.",
            'pipeline-objective-title': "Objectif du Projet",
            'pipeline-objective-p1': "L'objectif principal de ce projet est de d√©velopper et d'appliquer un pipeline bioinformatique rigoureux pour l'analyse de donn√©es de s√©quen√ßage du g√©nome. En utilisant l'√©chantillon public SRR24002947 comme √©tude de cas, nous visons √† identifier, annoter et interpr√©ter les mutations germinales, c'est-√†-dire les alt√©rations g√©n√©tiques h√©r√©ditaires, qui pourraient √™tre impliqu√©es dans la pr√©disposition aux cancers familiaux. Ce travail illustre les √©tapes cl√©s allant du traitement des donn√©es brutes de s√©quen√ßage √† l'√©valuation de l'impact potentiel des variants g√©n√©tiques d√©couverts, notamment sur des g√®nes d'int√©r√™t majeur comme BRCA1 et BRCA2. √Ä travers cette d√©marche, nous cherchons √† d√©montrer l'apport concret de la bioinformatique dans la compr√©hension des bases g√©n√©tiques des maladies h√©r√©ditaires et √† pr√©senter ce processus complexe de mani√®re claire et interactive via cette plateforme web.",
            'pipeline-projet-title': "Description du Pipeline Bioinformatique R√©alis√© sur Galaxy",
            'pipeline-intro-srr': "Pour illustrer concr√®tement l'analyse des mutations germinales dans les cancers familiaux, notre travail s'est concentr√© sur l'√©chantillon public <a href=\"https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>SRR24002947</strong></a>. Cet √©chantillon est issu du projet de recherche <a href=\"https://www.ncbi.nlm.nih.gov/bioproject/PRJNA949945\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>PRJNA949945</strong></a>, une √©tude d√©di√©e √† la caract√©risation du profil des mutations germinales des g√®nes cruciaux <strong>BRCA1 et BRCA2</strong> au sein de la population marocaine atteinte de cancer du sein. Comme le souligne cette √©tude, le cancer du sein est une pathologie majeure, et environ 20% des cas pr√©sentent une composante h√©r√©ditaire o√π les mutations de BRCA1/2 jouent un r√¥le pr√©pond√©rant. L'identification des porteurs de telles mutations est donc essentielle non seulement pour la pr√©vention et la d√©tection pr√©coce, mais aussi pour orienter vers une m√©decine personnalis√©e et des strat√©gies de chimiopr√©vention adapt√©es. L'objectif de l'√©tude PRJNA949945 est ainsi d'approfondir les connaissances sur les facteurs de risque g√©n√©tiques sp√©cifiques au Maroc.",
            'pipeline-intro-tech': "Les donn√©es de l'√©chantillon SRR24002947 ont √©t√© g√©n√©r√©es gr√¢ce √† des techniques de <strong>s√©quen√ßage de nouvelle g√©n√©ration (NGS)</strong>, plus pr√©cis√©ment par s√©quen√ßage <strong>Ion Torrent Proton</strong>. Cette approche a utilis√© le panel cibl√© <strong>Oncomine BRCA1 et BRCA2</strong> sur de l'ADN g√©nomique humain, suivant une strat√©gie de s√©quen√ßage d'amplicons (layout SINGLE). Il est √† noter que l'assemblage de r√©f√©rence initialement associ√© √† ces donn√©es sur SRA est <strong>GRCh37</strong>.",
            'pipeline-intro-analysis': "Notre pipeline bioinformatique, que nous avons impl√©ment√© sur la plateforme <strong>UseGalaxy.eu</strong>, a √©t√© con√ßu pour traiter ces donn√©es brutes. Pour notre analyse, nous avons align√© les lectures sur la version <strong>GRCh38/hg38</strong> du g√©nome de r√©f√©rence humain, afin d'identifier les variants potentiels au sein des s√©quences des g√®nes BRCA1 et BRCA2. Ces variants ont ensuite √©t√© annot√©s en utilisant des bases de donn√©es comme ClinVar et des outils comme Mutalyzer pour √©valuer leur pathog√©nicit√© √©ventuelle. Les √©tapes d√©taill√©es de ce pipeline sont d√©crites ci-dessous :",
            'pipeline-step1-title': "1. Contr√¥le Qualit√© Initial des Lectures Brutes",
            'pipeline-step-tool': "Outil Galaxy :", 'pipeline-step-obj': "Objectif :",
            'pipeline-step1-cap': "Figure: Rapport FastQC initial.",
            'pipeline-step2-title': "2. Nettoyage des Lectures (Trimmomatic)",
            'pipeline-step3-title': "3. Contr√¥le qualit√© apr√®s nettoyage",
            'pipeline-step3-cap': "Figure: Rapport FastQC apr√®s nettoyage.",
            'pipeline-step4-title': "4. Alignement sur le g√©nome de r√©f√©rence",
            'pipeline-step5-title': "5. Traitement du fichier BAM",
            'pipeline-step6-title': "6. Appel des variants",
            'pipeline-step7-title': "7. Annotation des variants avec SnpEff",
            'pipeline-step7-cap': "Figure: Rapport SnpEff_eff.",
            'pipeline-step8-title': "üìä 8. Sch√©ma R√©capitulatif du Pipeline sur Galaxy",
            'pipeline-step8-p1': "Workflow global impl√©ment√© dans Galaxy :",
            'pipeline-step8-cap': "Figure: Workflow Galaxy utilis√©.",
            'pipeline-resultats-title': "R√©sultats de l'Analyse de SRR24002947",
            'pipeline-resultats-stats': "Statistiques du Pipeline :",
            'pipeline-stat-raw': "Nombre total de lectures brutes : 3,675,752 ",
            'pipeline-stat-clean': "Nombre de lectures apr√®s nettoyage : <strong>3,670,123</strong>",
            'pipeline-stat-align': "Taux d'alignement : <strong>99.85%</strong>",
            'pipeline-stat-varraw': "Nombre de variants bruts : <strong>25</strong>",
            'pipeline-stat-varfilt': "Nombre de variants apr√®s filtration : <strong>25</strong>",
            'pipeline-stat-varclinvar': "Nombre de variants ClinVar (Pathogenic/Likely Pathogenic) : <strong>2</strong>",
            'pipeline-resultats-muttable': "Tableau des Mutations d'Int√©r√™t Identifi√©es :",
            'muttable-chr': "Chr", 'muttable-pos': "Pos (GRCh38)", 'muttable-gene': "G√®ne",
            'muttable-eff': "Effet Pr√©dit", 'muttable-hgvsc': "HGVS (c.)", 'muttable-hgvsp': "HGVS (p.)",
            'muttable-clnsig': "Signification Clinique",
            'pipeline-resultats-note': "Note : Les positions et nomenclatures sont bas√©es sur GRCh38 et les transcrits de r√©f√©rence (NM_007294.4 pour BRCA1, NM_000059.4 pour BRCA2).",
            'vep-title': "Annotation Compl√©mentaire avec VEP",
            'vep-desc': "Pour une meilleure annotation et pour corroborer les r√©sultats, nous avons utilis√© le Variant Effect Predictor (VEP) d'Ensembl comme outil externe √† Galaxy. VEP fournit une analyse d√©taill√©e des cons√©quences des variants sur les g√®nes, transcrits, et prot√©ines, en s'appuyant sur un large √©ventail de sources de donn√©es, ce qui enrichit l'interpr√©tation de leur impact potentiel.",
            'vep-caption-1': ".", 'vep-caption-2': ".", 'vep-caption-3': ".",
            'interpretation-main-title': "Interpr√©tation des Variants G√©n√©tiques",
            'interpretation-method-intro': "L'identification de variants g√©n√©tiques par s√©quen√ßage de nouvelle g√©n√©ration (NGS) n'est que la premi√®re √©tape d'une analyse complexe. Le d√©fi majeur r√©side dans l'interpr√©tation de ces variants afin de d√©terminer leur pertinence clinique, notamment dans le contexte des maladies h√©r√©ditaires comme les cancers familiaux. Ce processus implique l'utilisation d'outils bioinformatiques pour pr√©dire l'effet fonctionnel des mutations sur les g√®nes et les prot√©ines (par exemple, via VEP/SnpEff), la standardisation de leur nomenclature (avec des outils comme Mutalyzer), et leur comparaison avec des bases de donn√©es cliniques exhaustives (telles que ClinVar) qui recensent les variants connus et leur association avec des ph√©notypes.",
            'interpretation-project-focus': "Dans le cadre de ce projet, apr√®s l'application de notre pipeline bioinformatique sur l'√©chantillon SRR24002947, nous avons proc√©d√© √† cette d√©marche d'interpr√©tation pour les variants identifi√©s. Nous illustrons ci-dessous ce processus avec les mutations notables issues de notre analyse (<strong class=\"highlight\">BRCA1 c.116G>A</strong> et <strong class=\"highlight\">BRCA2 c.728del</strong>), ainsi que d'autres exemples de mutations fr√©quemment impliqu√©es dans les syndromes de pr√©disposition au cancer.",
            'mut-brca1-c116-title': "Variant de l'√âchantillon : G√®ne <span class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</span> - <span class=\"highlight\">NM_007294.4:c.116G>A</span>",
            'mut-brca1-c116-def-title': "D√©finition de la mutation",
            'mut-brca1-c116-def-p1': "La mutation √©tudi√©e est <strong class=\"highlight\">NM_007294.4:c.116G>A</strong> dans le g√®ne <strong class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</strong>. Cette notation signifie qu‚Äôau niveau du 116·µâ nucl√©otide de la s√©quence codante de l‚ÄôARN messager, la base guanine (G) est remplac√©e par une ad√©nine (A).",
            'mut-brca1-c116-def-p2': "Cette substitution provoque un changement dans le codon correspondant √† l‚Äôacide amin√© <strong class=\"highlight\">Cyst√©ine (Cys)</strong> en un codon codant pour la <strong class=\"highlight\">Tyrosine (Tyr)</strong> √† la position 39 de la prot√©ine BRCA1. Il s'agit donc d'une mutation <strong class=\"highlight\">faux-sens (missense)</strong> not√©e <strong class=\"highlight\">p.Cys39Tyr</strong> (ou p.C39Y).",
            'mut-brca1-c116-caption': "Figure : Mutation faux-sens c.116G>A (BRCA1). Cliquez pour Mutalyzer.",
            'mut-brca1-c116-eff-title': "Effets et cons√©quences",
            'mut-brca1-c116-eff-p1': "La cyst√©ine est un acide amin√© petit et faiblement polaire avec un groupe thiol important pour la stabilit√© de la prot√©ine. La tyrosine est plus volumineuse, polaire et aromatique, capable de participer √† la phosphorylation. Le remplacement de la cyst√©ine par la tyrosine peut modifier la structure et la fonction de la prot√©ine BRCA1.",
            'mut-brca1-c116-eff-p2': "BRCA1 est une prot√©ine suppresseur de tumeur essentielle √† la r√©paration des cassures double-brin de l‚ÄôADN par recombinaison homologue. La mutation <strong class=\"highlight\">p.Cys39Tyr</strong> peut perturber la structure du <strong class=\"highlight\">domaine RING</strong> √† l'extr√©mit√© N-terminale, qui est crucial pour l'ubiquitination, l'interaction avec BARD1, et le recrutement sur les sites de l√©sion de l'ADN. Une alt√©ration de cette fonction rend la cellule plus vuln√©rable aux mutations, favorisant la canc√©rogen√®se.",
            'mut-brca1-protein-viz-title': "Visualisation de l'effet prot√©ique",
            'mut-brca1-protein-caption': "Figure : Visualisation de l'effet prot√©ique p.Cys39Tyr (BRCA1). Cliquez pour Mutalyzer.",
            'mut-brca2-c728-title': "Variant de l'√âchantillon : G√®ne <span class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</span> - <span class=\"highlight\">NM_000059.4:c.728del</span>",
            'mut-brca2-c728-def-title': "D√©finition et cons√©quences",
            'mut-brca2-c728-def-p1': "La mutation <strong class=\"highlight\">NM_000059.4:c.728del</strong> dans le g√®ne <strong class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</strong> correspond √† la suppression d‚Äôun nucl√©otide √† la position 728 du transcrit codant.",
            'mut-brca2-c728-def-p2': "Cette d√©l√©tion d‚Äôun seul nucl√©otide provoque un <strong class=\"highlight\">d√©calage du cadre de lecture (frameshift)</strong>, modifiant tous les codons en aval et menant √† l'apparition d'un <strong class=\"highlight\">codon stop pr√©matur√©</strong>. La prot√©ine BRCA2 r√©sultante est tronqu√©e et non fonctionnelle.",
            'mut-brca2-c728-caption': "Figure : Mutation d√©calante c.728del (BRCA2). Cliquez pour Mutalyzer.",
            'mut-brca2-c728-eff-title': "Implications cliniques",
            'mut-brca2-c728-eff-p1': "BRCA2 est un g√®ne suppresseur de tumeur crucial dans la r√©paration de l'ADN par recombinaison homologue. La perte de sa fonction favorise l'accumulation de mutations et le d√©veloppement de cancers.",
            'mut-brca2-c728-eff-p2': "Les mutations d√©l√©t√®res comme <strong class=\"highlight\">c.728del</strong> sont associ√©es √† un risque √©lev√© de cancers h√©r√©ditaires (sein, ovaire, prostate, pancr√©as). √âtant une mutation germinale, son d√©pistage est crucial pour la pr√©vention et le suivi m√©dical des familles √† risque.",
            'mut-brca2-protein-viz-title': "Visualisation de l'effet prot√©ique",
            'mut-brca2-protein-caption': "Figure : Visualisation de l'effet prot√©ique p.Ser243IlefsTer5 (BRCA2). Cliquez pour Mutalyzer.",
            'interpretation-freq-mut-header': "Exemples Illustratifs de Mutations Fr√©quentes et Leurs Impacts",
            'ex-table-gene': "G√®ne", 'ex-table-type': "Type de Mutation", 'ex-table-exon': "Exon", 'ex-table-nuc': "Changement Nucl√©otidique",
            'ex-table-aa': "Changement Acide Amin√©", 'ex-table-tumor': "Syndrome / Tumeur Associ√©",
            'ex-table-tp53-type': "Faux-sens (Missense)", 'ex-table-tp53-syndrome': "Syndrome de Li-Fraumeni (sarcomes, seins, cerveau...)",
            'ex-table-msh2-type': "Non-sens (Nonsense)", 'ex-table-msh2-syndrome': "Syndrome de Lynch (colorectal, endom√®tre...)",
            'ex-table-msh6-type': "Frameshift", 'ex-table-msh6-syndrome': "Syndrome de Lynch, Cancer de l'endom√®tre",
            'ex-table-mlh1-type': "Non-sens (Nonsense)", 'ex-table-mlh1-syndrome': "Syndrome de Lynch (colorectal, endom√®tre...)",
            'ex-table-pten-type': "Faux-sens (Missense)", 'ex-table-pten-syndrome': "Syndrome de Cowden (sein, thyro√Øde, endom√®tre)",
            'ex-table-apc-type': "Non-sens (Nonsense)", 'ex-table-apc-syndrome': "Polypose ad√©nomateuse familiale (PAF)",
            'database-title': "Base de Donn√©es du Projet",
            'database-intro': "On a cr√©√© une base de donn√©es a pour but de centraliser et structur√© les informations g√©n√©tiques li√©es aux cancers d‚Äôorigine familiale. Elle permet l‚Äô√©tude des g√®nes associ√©s au cancer, les mutations (variants) identifi√©es chez les patients, ainsi que les amorces utilis√©es pour le s√©quen√ßage ou l‚Äôamplification de l‚ÄôADN La base contient trois tables principales: G√®ne, Variant, et Amorce.",
            'database-implementation-title': "Impl√©mentation et Acc√®s",
            'database-implementation-desc1': "La base de donn√©es a √©t√© cr√©√©e sous MySQL via phpMyAdmin, accessible gr√¢ce au serveur local EasyPHP. Les donn√©es issues du fichier VCF final (apr√®s annotation et filtration) ont √©t√© pars√©es et ins√©r√©es dans cette table.",
            'database-implementation-desc2': "Bien que cette base de donn√©es soit actuellement locale, cette approche d√©montre la faisabilit√© de stocker et g√©rer les r√©sultats d'analyses g√©nomiques de mani√®re structur√©e. Pour un projet √† plus grande √©chelle, cette base pourrait √™tre h√©berg√©e sur un serveur distant et accessible via une interface web d√©di√©e pour des requ√™tes et visualisations.",
            'db-fig1-caption': "Figure : Base de donn√©es - Structure globale (projet L3).",
            'db-table-gene-title': "1. Table : G√®ne",
            'db-table-gene-desc': "Contient les informations sur les g√®nes √©tudi√©s notamment ceux li√©s au cancer h√©r√©ditaire comme BRCA1, BRCA2, TP53, MLH1, APC, MSH2, MSH6, PTEN. Les informations sont: ID-g√®ne (d√©fini comme cl√© primaire), Nom-complet, s√©quence-g√®ne.",
            'db-fig2-caption': "Figure : Structure de la table G√®ne(01).",
            'db-fig3-caption': "Figure : Structure de la table G√®ne(02).",
            'db-table-variant-title': "2. Table : Variant",
            'db-table-variant-desc': "Contient les mutations (variants) identifi√©es sur les g√®nes √©tudi√©s et contient des informations comme: ID-variant (d√©fini comme cl√© primaire), type-variant (on a introduit 2 types de mutations pour chaque g√®ne), position-variant, longueur-variant et ID-g√®ne (d√©fini comme cl√© √©trang√®re).",
            'db-fig4-caption': "Figure : Donn√©es exemple de la table Variant (1).",
            'db-fig5-caption': "Figure : Donn√©es exemple de la table Variant (2).",
            'db-table-amorce-title': "3. Table : Amorce",
            'db-table-amorce-desc': "Contient les amorces (primers) utilis√©es pour amplifier des segments sp√©cifiques des g√®nes afin de d√©tecter les variants. Les informations identifi√©es dans cette table sont : id_amorce (d√©fini comme cl√© primaire), s√©quence_amorce (on a pris 2 amorces pour chaque g√®ne et chaque amorce √† deux s√©quences ‚Äús√©quence forward‚Äù, ‚Äús√©quence reverse‚Äù), la taille, le pourcentage GC, position start, position stop, temp√©rature, id_g√®ne (d√©fini comme cl√© √©trang√®re).",
            'db-fig6-caption': "Figure : Structure de la table Amorce(01).",
            'db-fig7-caption': "Figure : Donn√©es exemple de la table Amorce(02).",
            'database-future': "<strong>Perspectives :</strong> Des d√©veloppements futurs pourraient inclure la cr√©ation d'une interface PHP simple pour interroger et afficher les donn√©es de cette base, ou l'int√©gration avec des outils de visualisation.",
            'db-schema-relationnel-title': "Sch√©ma Relationnel",
            'db-schema-relationnel-desc': "Ce sch√©ma repr√©sente un mod√®le de base de donn√©es relationnelle. Ce mod√®le de donn√©es repr√©sente la relation entre les amorces, les g√®nes et les variants g√©n√©tiques. Il permet d'organiser et d'analyser les donn√©es g√©n√©tiques en reliant chaque g√®ne √† ses amorces et variants connus. Cette structure est utile pour √©tudier les mutations et leur impact potentiel en recherche ou en diagnostic.",
            'db-relation-amorce-gene-title': "Relations : amorce ‚Üí g√®nes",
            'db-relation-amorce-gene-card': "Cardinalit√© : (N,1) du c√¥t√© amorce vers (1,1) du c√¥t√© g√®nes",
            'db-relation-amorce-gene-exp': "‚û§ Un g√®ne peut avoir plusieurs amorces, mais une amorce est li√©e √† un seul g√®ne.",
            'db-relation-variant-gene-title': "Relations : variant ‚Üí g√®nes",
            'db-relation-variant-gene-card': "Cardinalit√© : (1,N) du c√¥t√© variant vers (1,1) du c√¥t√© g√®nes",
            'db-relation-variant-gene-exp': "‚û§ Un g√®ne peut poss√©der plusieurs variants, mais un variant appartient √† un seul g√®ne.",
            'db-interpretation-conceptuelle-title': "Interpr√©tation conceptuelle",
            'db-interpretation-conceptuelle-intro': "Ce mod√®le permet de :",
            'db-concept-point1': "Centraliser l‚Äôinformation sur des g√®nes cibles.",
            'db-concept-point2': "Associer √† chaque g√®ne les amorces PCR con√ßues pour son amplification.",
            'db-concept-point3': "Lister les variants g√©n√©tiques identifi√©s dans chaque g√®ne, utile en recherche ou diagnostic.",
            'db-fig8-caption': "Figure : Sch√©ma relationnel de la base de donn√©es.",
            'conclusion-title': "Conclusion",
            'conclusion-p1': "Ce mini-projet a permis de mettre en ≈ìuvre un pipeline bioinformatique complet pour l'analyse des donn√©es de s√©quen√ßage du g√©nome entier, en se concentrant sur l'identification des mutations germinales potentiellement impliqu√©es dans les cancers familiaux. En utilisant l'√©chantillon SRR24002947 et en √©tudiant des exemples de mutations connues (<strong class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</strong>, <strong class=\"gene-info-trigger\" data-gene=\"MLH1\">MLH1</strong>, <strong class=\"gene-info-trigger\" data-gene=\"TP53\">TP53</strong>, <strong class=\"gene-info-trigger\" data-gene=\"MSH2\">MSH2</strong>), nous avons illustr√© les √©tapes cruciales, allant du contr√¥le qualit√© des donn√©es brutes √† l'annotation et √† l'interpr√©tation fonctionnelle et clinique des variants.",
            'conclusion-p2': "L'importance d'une d√©marche rigoureuse, incluant l'alignement pr√©cis sur un g√©nome de r√©f√©rence, l'appel de variants sensible et sp√©cifique, et une annotation approfondie √† l'aide de bases de donn√©es comme ClinVar et d'outils comme SnpEff et Mutalyzer, a √©t√© soulign√©e. Nous avons vu comment ces outils permettent de classer les variants en fonction de leur pathog√©nicit√© pr√©sum√©e et de leur impact biologique, ce qui est essentiel pour le conseil g√©n√©tique et la prise en charge clinique des patients et de leurs familles.",
            'conclusion-p3': "La cr√©ation d'une base de donn√©es locale pour stocker les r√©sultats d√©montre une approche structur√©e pour la gestion des donn√©es g√©nomiques, bien que pour des applications r√©elles, des syst√®mes plus robustes et s√©curis√©s soient n√©cessaires.",
            'conclusion-p4': "Les d√©fis persistent, notamment dans l'interpr√©tation des variants de signification incertaine (VUS), qui requi√®rent des recherches fonctionnelles suppl√©mentaires et une collaboration internationale pour leur classification. N√©anmoins, les avanc√©es en bioinformatique et en g√©nomique continuent de transformer notre compr√©hension des cancers h√©r√©ditaires, ouvrant la voie √† une m√©decine de plus en plus personnalis√©e et pr√©ventive.",
            'conclusion-p5': "En d√©finitive, ce projet a non seulement consolid√© nos comp√©tences techniques en bioinformatique, mais a √©galement renforc√© notre appr√©ciation de la complexit√© et de l'impact de la g√©n√©tique dans le domaine de l'oncologie. Les outils et m√©thodes explor√©s ici sont au c≈ìur de la recherche actuelle et future pour lutter contre les cancers familiaux.",
            'ref-title': "R√©f√©rences Bibliographiques",
            'contact': "Contactez-nous",
            'ref-sra-sample': "NCBI Sequence Read Archive. Submission SRR24002947 (BioProject PRJNA949945). Acc√©d√© le [Date d'acc√®s]. Disponible sur : <a href=\"https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947\" target=\"_blank\">https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947</a>",
            'ref-grobner': "Gr√∂bner, S. N., Worst, B. C., Weischenfeldt, J., et al. (2018). The landscape of genomic alterations across childhood cancers. <em>Nature</em>, 555(7696), 321‚Äì327. <a href=\"https://doi.org/10.1038/nature25480\" target=\"_blank\">https://doi.org/10.1038/nature25480</a>",
            'ref-nccn': "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines¬Æ). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2024 (ou la version que vous avez consult√©e). National Comprehensive Cancer Network. Acc√©d√© le [Date d'acc√®s]. Disponible sur : [Lien si possible, sinon mentionner NCCN.org]",
            'ref-petrucelli': "Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010, r√©vis√© 2023). BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In Adam, M. P., et al. (Eds.), <em>GeneReviews¬Æ</em>. University of Washington, Seattle. Acc√©d√© le [Date d'acc√®s]. Disponible sur : <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1247/\" target=\"_blank\">https://www.ncbi.nlm.nih.gov/books/NBK1247/</a>",
            'ref-acmg': "Richards, S., Aziz, N., Bale, S., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. <em>Genetics in Medicine</em>, 17(5), 405‚Äì424. <a href=\"https://doi.org/10.1038/gim.2015.30\" target=\"_blank\">https://doi.org/10.1038/gim.2015.30</a>",
            'ref-fastqc': "Andrews, S. (2010). FastQC: A Quality Control tool for High Throughput Sequence Data. Disponible sur : <a href=\"http://www.bioinformatics.babraham.ac.uk/projects/fastqc/\" target=\"_blank\">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</a>",
            'ref-trimmomatic': "Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. <em>Bioinformatics</em>, 30(15), 2114‚Äì2120. <a href=\"https://doi.org/10.1093/bioinformatics/btu170\" target=\"_blank\">https://doi.org/10.1093/bioinformatics/btu170</a>",
            'ref-bowtie2': "Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. <em>Nature Methods</em>, 9(4), 357‚Äì359. <a href=\"https://doi.org/10.1038/nmeth.1923\" target=\"_blank\">https://doi.org/10.1038/nmeth.1923</a>",
            'ref-samtools': "Li, H., Handsaker, B., Wysoker, A., et al. (2009). The Sequence Alignment/Map format and SAMtools. <em>Bioinformatics</em>, 25(16), 2078‚Äì2079. <a href=\"https://doi.org/10.1093/bioinformatics/btp352\" target=\"_blank\">https://doi.org/10.1093/bioinformatics/btp352</a> (Pour Samtools) et Danecek, P., Bonfield, J.K., Liddle, J. et al. (2021) Twelve years of SAMtools and BCFtools. <em>GigaScience</em>, 10(2), giab008. <a href=\"https://doi.org/10.1093/gigascience/giab008\" target=\"_blank\">https://doi.org/10.1093/gigascience/giab008</a> (Pour Bcftools)",
            'ref-freebayes': "Garrison, E., & Marth, G. (2012). Haplotype-based variant detection from short-read sequencing. arXiv:1207.3907 [q-bio.GN]. Disponible sur : <a href=\"https://arxiv.org/abs/1207.3907\" target=\"_blank\">https://arxiv.org/abs/1207.3907</a>",
            'ref-snpeff': "Cingolani, P., Platts, A., Wang, L. L., et al. (2012). A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. <em>Fly</em>, 6(2), 80‚Äì92. <a href=\"https://doi.org/10.4161/fly.19695\" target=\"_blank\">https://doi.org/10.4161/fly.19695</a>",
            'ref-vep': "McLaren, W., Gil, L., Hunt, S. E., et al. (2016). The Ensembl Variant Effect Predictor. <em>Genome Biology</em>, 17(1), 122. <a href=\"https://doi.org/10.1186/s13059-016-0974-4\" target=\"_blank\">https://doi.org/10.1186/s13059-016-0974-4</a>",
            'ref-mutalyzer': "Wildeman, M., van Ophuizen, E., den Dunnen, J. T., & Taschner, P. E. (2008). Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. <em>Human Mutation</em>, 29(1), 6‚Äì13. <a href=\"https://doi.org/10.1002/humu.20611\" target=\"_blank\">https://doi.org/10.1002/humu.20611</a>",
            'ref-clinvar': "Landrum, M. J., Lee, J. M., Benson, M., et al. (2018). ClinVar: improving access to variant interpretations and supporting evidence. <em>Nucleic Acids Research</em>, 46(D1), D1062‚ÄìD1067. <a href=\"https://doi.org/10.1093/nar/gkx1153\" target=\"_blank\">https://doi.org/10.1093/nar/gkx1153</a>",
            'ref-galaxy': "Afgan, E., Baker, D., Batut, B., et al. (2018). The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. <em>Nucleic Acids Research</em>, 46(W1), W537‚ÄìW544. <a href=\"https://doi.org/10.1093/nar/gky379\" target=\"_blank\">https://doi.org/10.1093/nar/gky379</a> (Pour la plateforme Galaxy en g√©n√©ral)"
        },
        'en': {
            'login-title': "Access to Mini Project", 'login-btn': "Login",
            'home': "Home", 'intro-menu': "General Information", 'intro-generale-menu': "Introduction",
            'def-cf-menu': "Definition of Familial Cancers", 'types-cf-menu': "Types of Familial Cancers",
            'factors-cf-menu': "Risk Factors", 'symptoms-cf-menu': "Symptoms", 'stages-cf-menu': "Stages",
            'matmeth-projet-menu': "Materials & Methods", 'pipeline-projet-menu': "Project Pipeline",
            'interpretation-projet-menu': "Interpretation", 'database-menu': "Database",
            'conclusion-menu': "Conclusion", 'ref-menu': "References",
            'republique': "People's Democratic Republic of Algeria",
            'ministere': "Ministry of Higher Education and Scientific Research",
            'universite': "University of Fr√®res Mentouri Constantine 1",
            'faculte': "Faculty of Nature and Life Sciences",
            'departement': "Department of Applied Biology",
            'title': "Sequencing Data Processing Pipeline for the Study of Germline Mutations in Familial Cancers",
            'presented': "Presented by:", 'promo': "Class of 2026",
            'plan': "Work Plan",
            'plan-generality': "General Information", 'plan-intro': "‚Æï Introduction", 'plan-def-cf': "‚Æï Definition of Familial Cancers",
            'plan-types-cf': "‚Æï Types of Familial Cancers", 'plan-facteurs-cf': "‚Æï Risk Factors for Familial Cancers",
            'plan-symptomes-cf': "‚Æï Clinical Symptoms of Familial Cancers", 'plan-stades-cf': "‚Æï Stages of Familial Cancers",
            'plan-matmeth': "Project Materials and Methods", 'plan-pipeline': "Project Pipeline Description",
            'plan-resultats': "Project Results", 'plan-interpretation': "Interpretation of Results and Conclusion",
            'plan-database': "Project Database", 'plan-conclusion': "Conclusion", 'plan-ref': "Bibliographic References",
            'intro-generale-title': "Introduction",
            'intro-generale-p1': "Familial cancers represent a group of cancerous pathologies that appear with increased frequency in certain families due to hereditary genetic mutations. These mutations, transmitted in a Mendelian fashion from one generation to the next, significantly increase the risk of developing specific tumors.",
            'intro-generale-p2': "Understanding germline mutations, which affect reproductive cells and are therefore present in all cells of the body, is essential for early detection, targeted prevention, and personalized treatment of these familial cancers. This project aims to implement a bioinformatics pipeline to analyze sequencing data (sample SRR24002947) to identify such mutations.",
            'mutation-table-type': "Mutation Type", 'mutation-table-char': "Characteristics",
            'mutation-table-germ': "Germline Mutation", 'mutation-table-germ-desc': "Present in gametes (eggs and sperm) ‚Üí Transmitted to offspring ‚Üí Present in all cells of the body. Can increase cancer risk.",
            'mutation-table-som': "Somatic Mutation", 'mutation-table-som-desc': "Acquired during life in a non-germline cell ‚Üí Not hereditary ‚Üí Affects only a subset of cells (e.g., a tumor). Main cause of sporadic cancers.",
            'def-cf-title': "Definition of Familial Cancers",
            'def-cf-p1': "Familial (or hereditary) cancers are neoplasms for which genetic predisposition is inherited in a Mendelian pattern. Unlike sporadic cancers, which occur randomly under the influence of environmental factors and acquired somatic mutations, familial cancers are primarily linked to constitutional (germline) mutations transmitted vertically from one generation to the next.",
            'def-cf-p2': "These pathogenic mutations generally affect key genes involved in:",
            'def-cf-li1': "DNA damage repair (e.g., <strong class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</strong>, <strong class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</strong>, MMR system genes)",
            'def-cf-li2': "Cell cycle regulation (e.g., <strong class=\"gene-info-trigger\" data-gene=\"TP53\">TP53</strong>, RB1)",
            'def-cf-li3': "Intracellular signaling pathways (e.g., <strong class=\"gene-info-trigger\" data-gene=\"APC\">APC</strong>, <strong class=\"gene-info-trigger\" data-gene=\"PTEN\">PTEN</strong>)",
            'def-cf-li4': "Apoptosis (programmed cell death)",
            'def-cf-p3': "The presence of such a mutation does not mean that the individual will systematically develop cancer, but their risk is considerably increased compared to the general population.",
            'fig1cf': "Figure 01: Molecular mechanisms involved in familial cancers.",
            'types-cf-title': "Main Types of Familial Cancer Syndromes",
            'types-cf-h4-1': "1. Hereditary Breast and Ovarian Cancer Syndrome",
            'types-cf-p1': "Mainly due to mutations in the <strong class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</strong> and <strong class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</strong> genes, involved in DNA repair. Significantly increases the risk of:",
            'types-cf-li1': "40-85% risk of breast cancer (vs 12% in the general population)",
            'types-cf-li2': "10-40% risk of ovarian cancer (vs 1-2%)",
            'types-cf-li3': "Account for 5-10% of breast cancers and 15% of ovarian cancers",
            'types-cf-h4-2': "2. Hereditary Colorectal Cancer",
            'types-cf-p2': "Mainly associated with:",
            'types-cf-lynch': "Lynch Syndrome (genes <strong class=\"gene-info-trigger\" data-gene=\"MLH1\">MLH1</strong>, <strong class=\"gene-info-trigger\" data-gene=\"MSH2\">MSH2</strong>, <strong class=\"gene-info-trigger\" data-gene=\"MSH6\">MSH6</strong>, PMS2)",
            'types-cf-paf': "Familial Adenomatous Polyposis (gene <strong class=\"gene-info-trigger\" data-gene=\"APC\">APC</strong>)",
            'types-cf-li4': "Cumulative risk at 70 years: 50-80% (vs 5% in the general population)",
            'types-cf-h4-prostate': "3. Familial Prostate Cancer",
            'types-cf-p3': "Associated in particular with mutations:",
            'types-cf-li5': "<strong class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</strong> (risk increased by 5 to 8 times)",
            'types-cf-li6': "HOXB13",
            'types-cf-li7': "ATM, CHEK2",
            'types-cf-h4-lynchdetail': "4. Lynch Syndrome (details)",
            'types-cf-p4': "Increases the risk of:",
            'types-cf-li8': "Endometrial cancer (40-60% risk)",
            'types-cf-li9': "Ovarian cancer (10-12%)",
            'types-cf-li10': "Other cancers (stomach, small intestine, urinary tract)",
            'factors-cf-title': "Risk Factors for Familial Cancers",
            'factors-cf-li1': "<strong>Family history:</strong> Occurrence of similar cancers in several first-degree relatives (parents, siblings, children)",
            'factors-cf-li2': "<strong>Constitutional mutations:</strong> Pathogenic alterations in predisposition genes (<strong class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</strong>/<strong class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</strong>, <strong class=\"gene-info-trigger\" data-gene=\"APC\">APC</strong>, <strong class=\"gene-info-trigger\" data-gene=\"MLH1\">MLH1</strong>/<strong class=\"gene-info-trigger\" data-gene=\"MSH2\">MSH2</strong>, etc.)",
            'factors-cf-li3': "<strong>Early age of onset:</strong> Appearance of tumors at a significantly younger age than average",
            'factors-cf-li4': "<strong>Particular phenotype:</strong> Multiple tumors, specific locations, syndromic associations",
            'factors-cf-li5': "<strong>Epigenetic factors:</strong> Changes in gene expression without altering the DNA sequence",
            'factors-cf-li6': "<strong>Gene-environment interactions:</strong> Potentiation of risks by external factors (tobacco, alcohol, radiation)",
            'symptoms-cf-title': "Clinical Manifestations",
            'symptoms-cf-h4-sein': "Breast Cancer",
            'symptoms-cf-sein1': "Painless palpable lump", 'symptoms-cf-sein2': "Skin changes (orange peel skin, retraction)",
            'symptoms-cf-sein3': "Nipple discharge", 'symptoms-cf-sein4': "Axillary lymphadenopathy",
            'symptoms-cf-h4-colo': "Colorectal Cancer",
            'symptoms-cf-colo1': "Rectal bleeding", 'symptoms-cf-colo2': "Changes in bowel habits (diarrhea/constipation)",
            'symptoms-cf-colo3': "Persistent abdominal pain", 'symptoms-cf-colo4': "Unexplained iron-deficiency anemia",
            'symptoms-cf-h4-pros': "Prostate Cancer",
            'symptoms-cf-pros1': "Dysuria (difficulty urinating)", 'symptoms-cf-pros2': "Pollakiuria (frequent urination)",
            'symptoms-cf-pros3': "Hematuria (blood in urine)", 'symptoms-cf-pros4': "Pelvic or lower back pain",
            'symptoms-cf-h4-ova': "Ovarian Cancer",
            'symptoms-cf-ova1': "Abdominal bloating", 'symptoms-cf-ova2': "Chronic pelvic pain",
            'symptoms-cf-ova3': "Non-specific digestive issues", 'symptoms-cf-ova4': "Increased abdominal size",
            'stages-cf-title': "Cancer Staging",
            'stages-cf-p1': "The TNM (Tumor, Node, Metastasis) classification is used to assess the extent of familial cancers, as with sporadic forms:",
            'stages-table-stade': "Stage", 'stages-table-carac': "Characteristics", 'stages-table-prog': "Prognosis",
            'stages-cf-s1': "Stage I", 'stages-cf-s1d': "Localized tumor, confined to the original tissue", 'stages-cf-s1p': "Excellent (>90% 5-year survival)",
            'stages-cf-s2': "Stage II", 'stages-cf-s2d': "Local extension to adjacent tissues", 'stages-cf-s2p': "Good (70-90% survival)",
            'stages-cf-s3': "Stage III", 'stages-cf-s3d': "Involvement of regional lymph nodes", 'stages-cf-s3p': "Intermediate (30-70% survival)",
            'stages-cf-s4': "Stage IV", 'stages-cf-s4d': "Distant metastases (liver, lung, bone, etc.)", 'stages-cf-s4p': "Poor (<30% survival)",
            'matmeth-projet-title': "Materials and Methods",
            'matmeth-data-and-setup': "Data, Reference Genome, and Main Analysis Platform",
            'matmeth-projet-data': "Data Used:",
            'matmeth-projet-sample': "Sample: <a href=\"https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947\" target=\"_blank\" rel=\"noopener noreferrer\">SRR24002947</a> (accessible on NCBI SRA).",
            'matmeth-projet-type': "Data Type: Whole Genome Sequencing (WGS).",
            'matmeth-projet-origin': "Origin: Blood sample from a pediatric patient (Gr√∂bner et al., Nature 2018 study).",
            'matmeth-projet-refgenome': "Reference Genome:", 'matmeth-projet-refgenomeval': "GRCh38/hg38",
            'matmeth-projet-mainplatform': "Main Analysis Platform:",
            'matmeth-software-resources': "Software and Online Resources Used",
            'matmeth-software-intro': "To carry out this project, various software, analysis platforms, and databases were used:",
            'matmeth-configpc': "Configurations of Workstations Used:",
            'configpc-poste': "Workstation", 'configpc-carac': "Characteristic", 'configpc-val': "Value",
            'configpc-devname': "Device name", 'configpc-proc': "Processor", 'configpc-ram': "Installed RAM",
            'configpc-systype': "System type", 'configpc-winedition': "Windows edition", 'configpc-winver': "Windows version",
            'configpc-installdate': "Installed on", 'configpc-build': "OS build",
            'pipeline-whatis': "A Bioinformatics Pipeline",
            'pipeline-whatis-desc': "A bioinformatics pipeline is a structured sequence of steps or tools used to process, analyze, and interpret biological data, often in an automated manner. In the case of sequencing data, a pipeline allows moving from a raw file (like a FASTQ file) to the identification and annotation of genetic variants, through steps like quality control, trimming, alignment, and variant calling.",
            'pipeline-objective-title': "Project Objective",
            'pipeline-objective-p1': "The main objective of this project is to develop and apply a rigorous bioinformatics pipeline for the analysis of genome sequencing data. Using the public sample SRR24002947 as a case study, we aim to identify, annotate, and interpret germline mutations‚Äîthat is, hereditary genetic alterations‚Äîthat could be involved in the predisposition to familial cancers. This work illustrates the key steps from processing raw sequencing data to assessing the potential impact of the discovered genetic variants, particularly on major genes of interest such as BRCA1 and BRCA2. Through this process, we seek to demonstrate the concrete contribution of bioinformatics to understanding the genetic basis of hereditary diseases and to present this complex process clearly and interactively via this web platform.",
            'pipeline-projet-title': "Description of the Bioinformatics Pipeline Implemented on Galaxy",
            'pipeline-intro-srr': "To concretely illustrate the analysis of germline mutations in familial cancers, our work focused on the public sample <a href=\"https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>SRR24002947</strong></a>. This sample comes from the research project <a href=\"https://www.ncbi.nlm.nih.gov/bioproject/PRJNA949945\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>PRJNA949945</strong></a>, a study dedicated to characterizing the germline mutation profile of the crucial genes <strong>BRCA1 and BRCA2</strong> within the Moroccan population affected by breast cancer. As this study highlights, breast cancer is a major pathology, and about 20% of cases have a hereditary component where BRCA1/2 mutations play a predominant role. Identifying carriers of such mutations is therefore essential not only for prevention and early detection but also for guiding personalized medicine and tailored chemoprevention strategies. The objective of the PRJNA949945 study is thus to deepen the knowledge of genetic risk factors specific to Morocco.",
            'pipeline-intro-tech': "The data from sample SRR24002947 were generated using <strong>next-generation sequencing (NGS)</strong> techniques, specifically <strong>Ion Torrent Proton</strong> sequencing. This approach used the targeted <strong>Oncomine BRCA1 and BRCA2</strong> panel on human genomic DNA, following an amplicon sequencing strategy (SINGLE layout). It should be noted that the reference assembly initially associated with this data on SRA is <strong>GRCh37</strong>.",
            'pipeline-intro-analysis': "Our bioinformatics pipeline, implemented on the <strong>UseGalaxy.eu</strong> platform, was designed to process this raw data. For our analysis, we aligned the reads to the <strong>GRCh38/hg38</strong> version of the human reference genome to identify potential variants within the BRCA1 and BRCA2 gene sequences. These variants were then annotated using databases like ClinVar and tools like Mutalyzer to assess their potential pathogenicity. The detailed steps of this pipeline are described below:",
            'pipeline-step1-title': "1. Initial Quality Control of Raw Reads",
            'pipeline-step-tool': "Galaxy Tool:", 'pipeline-step-obj': "Objective:",
            'pipeline-step1-cap': "Figure: Initial FastQC report.",
            'pipeline-step2-title': "2. Read Trimming (Trimmomatic)",
            'pipeline-step3-title': "3. Quality Control After Trimming",
            'pipeline-step3-cap': "Figure: FastQC report after trimming.",
            'pipeline-step4-title': "4. Alignment to the Reference Genome",
            'pipeline-step5-title': "5. BAM File Processing",
            'pipeline-step6-title': "6. Variant Calling",
            'pipeline-step7-title': "7. Variant Annotation with SnpEff",
            'pipeline-step7-cap': "Figure: SnpEff_eff report.",
            'pipeline-step8-title': "üìä 8. Summary Diagram of the Pipeline on Galaxy",
            'pipeline-step8-p1': "Overall workflow implemented in Galaxy:",
            'pipeline-step8-cap': "Figure: Galaxy workflow used.",
            'pipeline-resultats-title': "Results of SRR24002947 Analysis",
            'pipeline-resultats-stats': "Pipeline Statistics:",
            'pipeline-stat-raw': "Total number of raw reads: 3,675,752",
            'pipeline-stat-clean': "Number of reads after trimming: <strong>3,670,123</strong>",
            'pipeline-stat-align': "Alignment rate: <strong>99.85%</strong>",
            'pipeline-stat-varraw': "Number of raw variants: <strong>25</strong>",
            'pipeline-stat-varfilt': "Number of variants after filtering: <strong>25</strong>",
            'pipeline-stat-varclinvar': "Number of ClinVar variants (Pathogenic/Likely Pathogenic): <strong>2</strong>",
            'pipeline-resultats-muttable': "Table of Identified Mutations of Interest:",
            'muttable-chr': "Chr", 'muttable-pos': "Pos (GRCh38)", 'muttable-gene': "Gene",
            'muttable-eff': "Predicted Effect", 'muttable-hgvsc': "HGVS (c.)", 'muttable-hgvsp': "HGVS (p.)",
            'muttable-clnsig': "Clinical Significance",
            'pipeline-resultats-note': "Note: Positions and nomenclatures are based on GRCh38 and reference transcripts (NM_007294.4 for BRCA1, NM_000059.4 for BRCA2).",
            'vep-title': "Complementary Annotation with VEP",
            'vep-desc': "For better annotation and to corroborate the results, we used Ensembl's Variant Effect Predictor (VEP) as an external tool to Galaxy. VEP provides a detailed analysis of the consequences of variants on genes, transcripts, and proteins, drawing on a wide range of data sources, which enriches the interpretation of their potential impact.",
            'vep-caption-1': ".", 'vep-caption-2': ".", 'vep-caption-3': ".",
            'interpretation-main-title': "Interpretation of Genetic Variants",
            'interpretation-method-intro': "Identifying genetic variants through next-generation sequencing (NGS) is only the first step in a complex analysis. The major challenge lies in interpreting these variants to determine their clinical relevance, especially in the context of hereditary diseases like familial cancers. This process involves using bioinformatics tools to predict the functional effect of mutations on genes and proteins (e.g., via VEP/SnpEff), standardizing their nomenclature (with tools like Mutalyzer), and comparing them against comprehensive clinical databases (such as ClinVar) that list known variants and their association with phenotypes.",
            'interpretation-project-focus': "As part of this project, after applying our bioinformatics pipeline to the SRR24002947 sample, we proceeded with this interpretation process for the identified variants. We illustrate this process below with the notable mutations from our analysis (<strong class=\"highlight\">BRCA1 c.116G>A</strong> and <strong class=\"highlight\">BRCA2 c.728del</strong>), as well as other examples of mutations frequently implicated in cancer predisposition syndromes.",
            'mut-brca1-c116-title': "Sample Variant: <span class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</span> Gene - <span class=\"highlight\">NM_007294.4:c.116G>A</span>",
            'mut-brca1-c116-def-title': "Definition of the mutation",
            'mut-brca1-c116-def-p1': "The mutation under study is <strong class=\"highlight\">NM_007294.4:c.116G>A</strong> in the <strong class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</strong> gene. This notation means that at the 116th nucleotide of the messenger RNA's coding sequence, the guanine (G) base is replaced by an adenine (A).",
            'mut-brca1-c116-def-p2': "This substitution causes a change in the codon for the amino acid <strong class=\"highlight\">Cysteine (Cys)</strong> to a codon for <strong class=\"highlight\">Tyrosine (Tyr)</strong> at position 39 of the BRCA1 protein. This is a <strong class=\"highlight\">missense</strong> mutation, denoted <strong class=\"highlight\">p.Cys39Tyr</strong> (or p.C39Y).",
            'mut-brca1-c116-caption': "Figure: Missense mutation c.116G>A (BRCA1). Click for Mutalyzer.",
            'mut-brca1-c116-eff-title': "Effects and consequences",
            'mut-brca1-c116-eff-p1': "Cysteine is a small, weakly polar amino acid with a thiol group important for protein stability. Tyrosine is bulkier, polar, and aromatic, capable of participating in phosphorylation. The replacement of cysteine with tyrosine can alter the structure and function of the BRCA1 protein.",
            'mut-brca1-c116-eff-p2': "BRCA1 is a tumor suppressor protein essential for the repair of DNA double-strand breaks through homologous recombination. The <strong class=\"highlight\">p.Cys39Tyr</strong> mutation can disrupt the structure of the N-terminal <strong class=\"highlight\">RING domain</strong>, which is crucial for ubiquitination, interaction with BARD1, and recruitment to DNA damage sites. An alteration of this function makes the cell more vulnerable to mutations, promoting carcinogenesis.",
            'mut-brca1-protein-viz-title': "Visualization of the protein effect",
            'mut-brca1-protein-caption': "Figure: Visualization of the p.Cys39Tyr protein effect (BRCA1). Click for Mutalyzer.",
            'mut-brca2-c728-title': "Sample Variant: <span class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</span> Gene - <span class=\"highlight\">NM_000059.4:c.728del</span>",
            'mut-brca2-c728-def-title': "Definition and consequences",
            'mut-brca2-c728-def-p1': "The mutation <strong class=\"highlight\">NM_000059.4:c.728del</strong> in the <strong class=\"gene-info-trigger\" data-gene=\"BRCA2\">BRCA2</strong> gene corresponds to the deletion of one nucleotide at position 728 of the coding transcript.",
            'mut-brca2-c728-def-p2': "This single-nucleotide deletion causes a <strong class=\"highlight\">frameshift</strong>, altering all downstream codons and leading to the appearance of a <strong class=\"highlight\">premature stop codon</strong>. The resulting BRCA2 protein is truncated and non-functional.",
            'mut-brca2-c728-caption': "Figure: Frameshift mutation c.728del (BRCA2). Click for Mutalyzer.",
            'mut-brca2-c728-eff-title': "Clinical implications",
            'mut-brca2-c728-eff-p1': "BRCA2 is a crucial tumor suppressor gene in DNA repair by homologous recombination. Loss of its function promotes the accumulation of mutations and the development of cancers.",
            'mut-brca2-c728-eff-p2': "Deleterious mutations like <strong class=\"highlight\">c.728del</strong> are associated with a high risk of hereditary cancers (breast, ovarian, prostate, pancreatic). As a germline mutation, its screening is crucial for prevention and medical follow-up of at-risk families.",
            'mut-brca2-protein-viz-title': "Visualization of the protein effect",
            'mut-brca2-protein-caption': "Figure: Visualization of the p.Ser243IlefsTer5 protein effect (BRCA2). Click for Mutalyzer.",
            'interpretation-freq-mut-header': "Illustrative Examples of Frequent Mutations and Their Impacts",
            'ex-table-gene': "Gene", 'ex-table-type': "Mutation Type", 'ex-table-exon': "Exon", 'ex-table-nuc': "Nucleotide Change",
            'ex-table-aa': "Amino Acid Change", 'ex-table-tumor': "Associated Syndrome / Tumor",
            'ex-table-tp53-type': "Missense", 'ex-table-tp53-syndrome': "Li-Fraumeni Syndrome (sarcomas, breast, brain...)",
            'ex-table-msh2-type': "Nonsense", 'ex-table-msh2-syndrome': "Lynch Syndrome (colorectal, endometrial...)",
            'ex-table-msh6-type': "Frameshift", 'ex-table-msh6-syndrome': "Lynch Syndrome, Endometrial Cancer",
            'ex-table-mlh1-type': "Nonsense", 'ex-table-mlh1-syndrome': "Lynch Syndrome (colorectal, endometrial...)",
            'ex-table-pten-type': "Missense", 'ex-table-pten-syndrome': "Cowden Syndrome (breast, thyroid, endometrium)",
            'ex-table-apc-type': "Nonsense", 'ex-table-apc-syndrome': "Familial Adenomatous Polyposis (FAP)",
            'database-title': "Project Database",
            'database-intro': "A database was created to centralize and structure genetic information related to familial cancers. It allows for the study of cancer-associated genes, mutations (variants) identified in patients, and primers used for DNA sequencing or amplification. The database contains three main tables: Gene, Variant, and Primer, populated with data from the SRR24002947 sample after bioinformatics analysis.",
            'database-implementation-title': "Implementation and Access",
            'database-implementation-desc1': "The database was created in MySQL via phpMyAdmin, accessible through the EasyPHP local server. Data from the final VCF file (after annotation and filtering) was parsed and inserted into this table.",
            'database-implementation-desc2': "Although this database is currently local, this approach demonstrates the feasibility of storing and managing genomic analysis results in a structured manner. For a larger-scale project, this database could be hosted on a remote server and accessed via a dedicated web interface for queries and visualizations.",
            'db-fig1-caption': "Figure: Database - Overall structure (L3 project).",
            'db-table-gene-title': "1. Table: Gene",
            'db-table-gene-desc': "Contains information on the studied genes, particularly those related to hereditary cancer such as BRCA1, BRCA2, TP53, MLH1, APC, MSH2, MSH6, PTEN. The information includes: Gene_ID (primary key), Full_Name, Gene_Sequence.",
            'db-fig2-caption': "Figure: Structure of the Gene table (01).",
            'db-fig3-caption': "Figure: Structure of the Gene table (02).",
            'db-table-variant-title': "2. Table: Variant",
            'db-table-variant-desc': "Contains the mutations (variants) identified in the studied genes and includes information such as: Variant_ID (primary key), Variant_Type (2 mutation types were introduced for each gene), Variant_Position, Variant_Length, and Gene_ID (foreign key).",
            'db-fig4-caption': "Figure: Sample data from the Variant table (1).",
            'db-fig5-caption': "Figure: Sample data from the Variant table (2).",
            'db-table-amorce-title': "3. Table: Primer",
            'db-table-amorce-desc': "Contains the primers used to amplify specific gene segments to detect variants. The information identified in this table is: primer_id (primary key), primer_sequence (we took 2 primers for each gene, each with a 'forward sequence' and 'reverse sequence'), size, GC percentage, start position, stop position, temperature, gene_id (foreign key).",
            'db-fig6-caption': "Figure: Structure of the Primer table (01).",
            'db-fig7-caption': "Figure: Sample data from the Primer table (02).",
            'database-future': "<strong>Future prospects:</strong> Future developments could include creating a simple PHP interface to query and display data from this database, or integrating it with visualization tools.",
            'db-schema-relationnel-title': "Relational Schema",
            'db-schema-relationnel-desc': "This schema represents a relational database model. This data model depicts the relationship between primers, genes, and genetic variants. It allows for organizing and analyzing genetic data by linking each gene to its known primers and variants. This structure is useful for studying mutations and their potential impact in research or diagnostics.",
            'db-relation-amorce-gene-title': "Relations: primer ‚Üí genes",
            'db-relation-amorce-gene-card': "Cardinality: (N,1) on the primer side to (1,1) on the gene side",
            'db-relation-amorce-gene-exp': "‚û§ A gene can have multiple primers, but a primer is linked to only one gene.",
            'db-relation-variant-gene-title': "Relations: variant ‚Üí genes",
            'db-relation-variant-gene-card': "Cardinality: (1,N) on the variant side to (1,1) on the gene side",
            'db-relation-variant-gene-exp': "‚û§ A gene can have multiple variants, but a variant belongs to only one gene.",
            'db-interpretation-conceptuelle-title': "Conceptual Interpretation",
            'db-interpretation-conceptuelle-intro': "This model allows for:",
            'db-concept-point1': "Centralizing information on target genes.",
            'db-concept-point2': "Associating each gene with the PCR primers designed for its amplification.",
            'db-concept-point3': "Listing the genetic variants identified in each gene, which is useful in research or diagnostics.",
            'db-fig8-caption': "Figure: Relational schema of the database.",
            'conclusion-title': "Conclusion",
            'conclusion-p1': "This mini-project successfully implemented a complete bioinformatics pipeline for analyzing whole-genome sequencing data, focusing on identifying germline mutations potentially involved in familial cancers. Using the SRR24002947 sample and studying examples of known mutations (<strong class=\"gene-info-trigger\" data-gene=\"BRCA1\">BRCA1</strong>, <strong class=\"gene-info-trigger\" data-gene=\"MLH1\">MLH1</strong>, <strong class=\"gene-info-trigger\" data-gene=\"TP53\">TP53</strong>, <strong class=\"gene-info-trigger\" data-gene=\"MSH2\">MSH2</strong>), we illustrated the crucial steps from raw data quality control to functional and clinical annotation and interpretation of variants.",
            'conclusion-p2': "The importance of a rigorous approach, including precise alignment to a reference genome, sensitive and specific variant calling, and in-depth annotation using databases like ClinVar and tools like SnpEff and Mutalyzer, was highlighted. We saw how these tools help classify variants based on their presumed pathogenicity and biological impact, which is essential for genetic counseling and the clinical management of patients and their families.",
            'conclusion-p3': "The creation of a local database to store the results demonstrates a structured approach to managing genomic data, although for real-world applications, more robust and secure systems are necessary.",
            'conclusion-p4': "Challenges persist, particularly in the interpretation of variants of uncertain significance (VUS), which require further functional research and international collaboration for their classification. Nevertheless, advances in bioinformatics and genomics continue to transform our understanding of hereditary cancers, paving the way for increasingly personalized and preventive medicine.",
            'conclusion-p5': "Ultimately, this project not only consolidated our technical skills in bioinformatics but also deepened our appreciation for the complexity and impact of genetics in the field of oncology. The tools and methods explored here are at the heart of current and future research in the fight against familial cancers.",
            'ref-title': "Bibliographic References",
            'contact': "Contact Us",
            'ref-sra-sample': "NCBI Sequence Read Archive. Submission SRR24002947 (BioProject PRJNA949945). Accessed [Access Date]. Available at: <a href=\"https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947\" target=\"_blank\">https://www.ncbi.nlm.nih.gov/sra/?term=SRR24002947</a>",
            'ref-grobner': "Gr√∂bner, S. N., Worst, B. C., Weischenfeldt, J., et al. (2018). The landscape of genomic alterations across childhood cancers. <em>Nature</em>, 555(7696), 321‚Äì327. <a href=\"https://doi.org/10.1038/nature25480\" target=\"_blank\">https://doi.org/10.1038/nature25480</a>",
            'ref-nccn': "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines¬Æ). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2024 (or the version you consulted). National Comprehensive Cancer Network. Accessed [Access Date]. Available at: [Link if possible, otherwise mention NCCN.org]",
            'ref-petrucelli': "Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010, revised 2023). BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In Adam, M. P., et al. (Eds.), <em>GeneReviews¬Æ</em>. University of Washington, Seattle. Accessed [Access Date]. Available at: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1247/\" target=\"_blank\">https://www.ncbi.nlm.nih.gov/books/NBK1247/</a>",
            'ref-acmg': "Richards, S., Aziz, N., Bale, S., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. <em>Genetics in Medicine</em>, 17(5), 405‚Äì424. <a href=\"https://doi.org/10.1038/gim.2015.30\" target=\"_blank\">https://doi.org/10.1038/gim.2015.30</a>",
            'ref-fastqc': "Andrews, S. (2010). FastQC: A Quality Control tool for High Throughput Sequence Data. Available at: <a href=\"http://www.bioinformatics.babraham.ac.uk/projects/fastqc/\" target=\"_blank\">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</a>",
            'ref-trimmomatic': "Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. <em>Bioinformatics</em>, 30(15), 2114‚Äì2120. <a href=\"https://doi.org/10.1093/bioinformatics/btu170\" target=\"_blank\">https://doi.org/10.1093/bioinformatics/btu170</a>",
            'ref-bowtie2': "Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. <em>Nature Methods</em>, 9(4), 357‚Äì359. <a href=\"https://doi.org/10.1038/nmeth.1923\" target=\"_blank\">https://doi.org/10.1038/nmeth.1923</a>",
            'ref-samtools': "Li, H., Handsaker, B., Wysoker, A., et al. (2009). The Sequence Alignment/Map format and SAMtools. <em>Bioinformatics</em>, 25(16), 2078‚Äì2079. <a href=\"https://doi.org/10.1093/bioinformatics/btp352\" target=\"_blank\">https://doi.org/10.1093/bioinformatics/btp352</a> (For Samtools) and Danecek, P., Bonfield, J.K., Liddle, J. et al. (2021) Twelve years of SAMtools and BCFtools. <em>GigaScience</em>, 10(2), giab008. <a href=\"https://doi.org/10.1093/gigascience/giab008\" target=\"_blank\">https://doi.org/10.1093/gigascience/giab008</a> (For Bcftools)",
            'ref-freebayes': "Garrison, E., & Marth, G. (2012). Haplotype-based variant detection from short-read sequencing. arXiv:1207.3907 [q-bio.GN]. Available at: <a href=\"https://arxiv.org/abs/1207.3907\" target=\"_blank\">https://arxiv.org/abs/1207.3907</a>",
            'ref-snpeff': "Cingolani, P., Platts, A., Wang, L. L., et al. (2012). A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. <em>Fly</em>, 6(2), 80‚Äì92. <a href=\"https://doi.org/10.4161/fly.19695\" target=\"_blank\">https://doi.org/10.4161/fly.19695</a>",
            'ref-vep': "McLaren, W., Gil, L., Hunt, S. E., et al. (2016). The Ensembl Variant Effect Predictor. <em>Genome Biology</em>, 17(1), 122. <a href=\"https://doi.org/10.1186/s13059-016-0974-4\" target=\"_blank\">https://doi.org/10.1186/s13059-016-0974-4</a>",
            'ref-mutalyzer': "Wildeman, M., van Ophuizen, E., den Dunnen, J. T., & Taschner, P. E. (2008). Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. <em>Human Mutation</em>, 29(1), 6‚Äì13. <a href=\"https://doi.org/10.1002/humu.20611\" target=\"_blank\">https://doi.org/10.1002/humu.20611</a>",
            'ref-clinvar': "Landrum, M. J., Lee, J. M., Benson, M., et al. (2018). ClinVar: improving access to variant interpretations and supporting evidence. <em>Nucleic Acids Research</em>, 46(D1), D1062‚ÄìD1067. <a href=\"https://doi.org/10.1093/nar/gkx1153\" target=\"_blank\">https://doi.org/10.1093/nar/gkx1153</a>",
            'ref-galaxy': "Afgan, E., Baker, D., Batut, B., et al. (2018). The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. <em>Nucleic Acids Research</em>, 46(W1), W537‚ÄìW544. <a href=\"https://doi.org/10.1093/nar/gky379\" target=\"_blank\">https://doi.org/10.1093/nar/gky379</a> (For the Galaxy platform in general)"
        }
    };


    let currentLanguage = 'fr';
    let modalCurrentGene = null; 

    function openInfoModal(geneNameOrImageSrc, caption) {
        // Check if it's a gene from our data object
        if (geneData[geneNameOrImageSrc]) { 
            modalCurrentGene = geneNameOrImageSrc;
            const data = geneData[geneNameOrImageSrc];
            modalTitle.textContent = currentLanguage === 'en' ? data.title_en : data.title;
            modalImage.style.display = 'none'; 
            modalFigcaption.textContent = ''; 
            
            let bodyContent = `<p><strong>Symbol:</strong> ${data.symbol}</p>`;
            bodyContent += `<p><strong>Full Name:</strong> ${currentLanguage === 'en' ? data.fullName_en : data.fullName}</p>`;
            bodyContent += `<p><strong>Gene ID:</strong> ${data.idGene}</p>`;
            bodyContent += `<h4>Definition:</h4><p>${currentLanguage === 'en' ? data.definition_en : data.definition}</p>`;
            modalBody.innerHTML = bodyContent;

        } else { // Otherwise, it's an image
            modalCurrentGene = null; 
            modalTitle.textContent = (caption || '').split(':')[0]; 
            modalImage.src = geneNameOrImageSrc;
            modalImage.style.display = 'block';
            modalFigcaption.textContent = caption || '';
            modalBody.innerHTML = '';
        }
        infoModal.style.display = 'flex';
    }


    function closeInfoModal() {
        infoModal.style.display = 'none';
        modalImage.src = ""; 
        modalCurrentGene = null;
    }

    
    window.onclick = function(event) {
        if (event.target == infoModal) {
            closeInfoModal();
        }
    }
    
    function applyTranslations() {
        const langData = translations[currentLanguage];
        document.querySelectorAll('[class*="lang-"]').forEach(el => {
            const langClass = Array.from(el.classList).find(cls => cls.startsWith('lang-'));
            if(langClass) {
                const key = langClass.substring(5);
                if (langData[key]) {
                    el.innerHTML = langData[key];
                }
            }
        });

        // Translate placeholders and titles specifically
        document.documentElement.lang = currentLanguage;
        document.getElementById('searchInput').placeholder = currentLanguage === 'fr' ? 'Rechercher...' : 'Search...';
        document.getElementById('username').placeholder = currentLanguage === 'fr' ? "Nom d'utilisateur" : "Username";
        document.getElementById('password').placeholder = currentLanguage === 'fr' ? "Mot de passe" : "Password";
        
        // Re-render modal if it's open and showing gene info
        if (infoModal.style.display === 'flex' && modalCurrentGene && geneData[modalCurrentGene]) {
            openInfoModal(modalCurrentGene); 
        }
    }

    function changeLanguage(lang) {
        currentLanguage = lang;
        document.getElementById('currentFlag').src = `https://flagcdn.com/w20/${lang === 'fr' ? 'fr' : 'gb'}.png`;
        document.getElementById('currentLangText').textContent = lang.toUpperCase();
        applyTranslations();
        document.getElementById('languageDropdownMenu').classList.remove('show-lang-dropdown');
    }

    function login() {
        if (document.getElementById('username').value === 'mm' && document.getElementById('password').value === 'mm') {
            document.getElementById('loginContainerForm').classList.add('hidden-form');
            setTimeout(() => {
                document.getElementById('loginScreen').classList.add('hidden');
                const mainContent = document.getElementById('mainContent');
                mainContent.classList.add('show');
                
                setTimeout(() => {
                     document.querySelectorAll('.tab-content.active > .is-visible').forEach(el => {
                         el.classList.remove('is-visible');
                         el.offsetHeight; 
                         el.classList.add('is-visible');
                     });
                     document.querySelectorAll('.tab-content.active > div, .tab-content.active > section').forEach(el => {
                         if (el.getBoundingClientRect().top < window.innerHeight) {
                            el.classList.add('is-visible');
                         }
                     });
                }, 100);
            }, 400);
        } else {
            alert(currentLanguage === 'fr' ? "Identifiants incorrects." : "Incorrect credentials.");
        }
    }

    function logout() {
        const mainContent = document.getElementById('mainContent');
        const logoutScreen = document.getElementById('logoutMessageScreen');
        const logoutText = document.getElementById('logoutMessageText');
        const loginScreen = document.getElementById('loginScreen');

        // D√©finir le message en fonction de la langue
        logoutText.textContent = currentLanguage === 'fr' 
            ? "Merci pour votre attention !" 
            : "Thank you for your attention!";

        mainContent.style.opacity = '0';
        document.querySelector('.navbar').style.transform = 'translateY(-100%)';
        
        setTimeout(() => {
            mainContent.classList.remove('show');
            mainContent.style.display = 'none';
            logoutScreen.style.display = 'flex';
            
            setTimeout(() => {
                logoutScreen.style.opacity = '1';
                logoutScreen.classList.add('show-message');
            }, 50);

        }, 800);

        setTimeout(() => {
            logoutScreen.style.opacity = '0';
            logoutScreen.classList.remove('show-message');
        }, 3500); 
        
        setTimeout(() => {
            logoutScreen.style.display = 'none';
            loginScreen.classList.remove('hidden');
            
            const loginForm = document.getElementById('loginContainerForm');
            loginForm.style.animation = 'none';
            loginForm.offsetHeight;
            loginForm.style.animation = null; 
            
            loginForm.classList.remove('hidden-form');
            document.getElementById('username').value = '';
            document.getElementById('password').value = '';
            
        }, 4200);
    }

    document.addEventListener('DOMContentLoaded', function() {
        const observerOptions = {
            root: null,
            rootMargin: '0px',
            threshold: 0.1 
        };

        const observer = new IntersectionObserver((entries, observer) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    entry.target.classList.add('is-visible');
                    observer.unobserve(entry.target);
                }
            });
        }, observerOptions);

        const targets = document.querySelectorAll('.content-section, .title-page, .institution-header, .figure, .data-table-container, .pipeline-step, .contact-card, .work-plan');
        targets.forEach(target => {
            observer.observe(target);
        });

        // --- Tab Navigation Logic ---
        const navLinks = document.querySelectorAll('.nav-tabs a:not(.dropdown-toggle)');
        const dropdownItems = document.querySelectorAll('.dropdown-menu a');

        function activateTab(targetId) {
            document.querySelectorAll('.tab-content').forEach(s => s.classList.remove('active'));
            const targetSection = document.getElementById(targetId);
            if (targetSection) {
                targetSection.classList.add('active');
                 setTimeout(() => {
                    targetSection.querySelectorAll('.content-section, .figure, .data-table-container, .pipeline-step, .contact-card, .title-page, .institution-header, .work-plan').forEach(el => {
                        observer.observe(el); 
                    });
                 }, 50);
            }

            document.querySelectorAll('.nav-tabs a').forEach(lnk => lnk.classList.remove('active'));
            let activeLink = document.querySelector(`.nav-tabs a[href="#${targetId}"]`);
            if (activeLink) {
                 activeLink.classList.add('active');
            } else { 
                activeLink = document.querySelector(`.dropdown-menu a[href="#${targetId}"]`);
                if(activeLink) {
                    const dropdownToggle = activeLink.closest('.nav-item.dropdown').querySelector('.dropdown-toggle');
                    if (dropdownToggle) dropdownToggle.classList.add('active'); 
                }
            }
        }

        function handleLinkClick(e) {
            e.preventDefault();
            const targetId = this.getAttribute('href').substring(1);
            history.pushState(null, '', '#' + targetId); 
            activateTab(targetId);
            const parentDropdownMenu = this.closest('.dropdown-menu');
            if (parentDropdownMenu) {
                parentDropdownMenu.classList.remove('show-dropdown');
            }
        }

        navLinks.forEach(link => link.addEventListener('click', handleLinkClick));
        dropdownItems.forEach(link => link.addEventListener('click', handleLinkClick));
        
        // --- Initial Load Logic ---
        if (window.location.hash) {
            const hash = window.location.hash.substring(1);
            if (document.getElementById(hash)) {
                 activateTab(hash);
            } else {
                 activateTab('home');
            }
        } else {
            activateTab('home');
        }
        
        window.addEventListener('popstate', () => {
             if (window.location.hash) {
                activateTab(window.location.hash.substring(1));
            } else {
                activateTab('home');
            }
        });

        // --- UI Controls ---
        document.getElementById('darkModeToggle').addEventListener('click', () => {
            document.body.classList.toggle('dark-mode');
            const icon = document.querySelector('#darkModeToggle i');
            icon.classList.toggle('fa-moon');
            icon.classList.toggle('fa-sun');
        });

        document.getElementById('mainContent').addEventListener('click', function(event) {
            const trigger = event.target.closest('.gene-info-trigger');
            if (trigger && trigger.dataset.gene) {
                openInfoModal(trigger.dataset.gene);
            }
        });
        
        // --- Search Logic ---
        const searchInput = document.getElementById('searchInput');
        
        function removeHighlights() {
            document.querySelectorAll('span.search-highlight').forEach(span => {
                const parent = span.parentNode;
                if (parent) {
                    parent.replaceChild(document.createTextNode(span.textContent), span);
                    parent.normalize(); // Fusionne les n≈ìuds de texte adjacents
                }
            });
        }
        
        searchInput.addEventListener('input', function() {
            if (this.value.trim() === '') {
                removeHighlights();
            }
        });

        searchInput.addEventListener('keyup', function(e) {
            if (e.key !== 'Enter') return;

            removeHighlights();

            const searchTerm = this.value.trim();
            if (searchTerm === '') return;

            const contentElements = document.querySelectorAll('.tab-content.active p, .tab-content.active li, .tab-content.active td, .tab-content.active h3, .tab-content.active h4, .tab-content.active h5, .tab-content.active strong, .tab-content.active span:not(.search-highlight)');
            let firstFoundElement = null;
            const regex = new RegExp(searchTerm.replace(/[.*+?^${}()|[\]\\]/g, '\\$&'), 'gi');
            
            contentElements.forEach(el => {
                if (el.closest('script, style, .search-highlight')) return;
                
                Array.from(el.childNodes).forEach(node => {
                    if (node.nodeType === Node.TEXT_NODE) {
                       const text = node.nodeValue;
                       if(regex.test(text)) {
                            if (!firstFoundElement) firstFoundElement = el;
                            const newHtml = text.replace(regex, match => `<span class="search-highlight">${match}</span>`);
                            const tempWrapper = document.createElement('div');
                            tempWrapper.innerHTML = newHtml;

                            while(tempWrapper.firstChild) {
                                el.insertBefore(tempWrapper.firstChild, node);
                            }
                            el.removeChild(node);
                       }
                    }
                });
            });

            if (firstFoundElement) {
                const highlightToScroll = document.querySelector('.search-highlight');
                if (highlightToScroll) {
                    highlightToScroll.scrollIntoView({ behavior: 'smooth', block: 'center' });
                }
            } else {
                alert(currentLanguage === 'fr' ? 'Aucun r√©sultat trouv√© dans l\'onglet actuel.' : 'No results found in the current tab.');
            }
        });

        // --- Dropdown Logic ---
        document.querySelectorAll('.dropdown-toggle, .language-btn').forEach(toggle => {
            toggle.addEventListener('click', function(event) {
                event.preventDefault(); event.stopPropagation();
                const menu = this.nextElementSibling;
                const isAlreadyOpen = menu.classList.contains('show-dropdown') || menu.classList.contains('show-lang-dropdown');
                
                document.querySelectorAll('.show-dropdown, .show-lang-dropdown').forEach(openMenu => {
                    if (openMenu !== menu) {
                       openMenu.classList.remove('show-dropdown', 'show-lang-dropdown');
                    }
                });

                if (!isAlreadyOpen) {
                    menu.classList.add(menu.classList.contains('language-dropdown') ? 'show-lang-dropdown' : 'show-dropdown');
                } else {
                    menu.classList.remove('show-dropdown', 'show-lang-dropdown');
                }
            });
        });

        document.addEventListener('click', function(event) {
            if (!event.target.closest('.dropdown, .language-selector')) {
                document.querySelectorAll('.show-dropdown, .show-lang-dropdown').forEach(openMenu => {
                    openMenu.classList.remove('show-dropdown', 'show-lang-dropdown');
                });
            }
        });
        
        if (typeof lightbox !== 'undefined') {
            lightbox.option({ 'resizeDuration': 200, 'wrapAround': true, 'fadeDuration': 300 });
        }

        applyTranslations();
    });
</script>
</body>
</html>